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ABSTRACT 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death 
in U.S. following cancer and heart disease. COPD is an umbrella term for two chronic 
pathological conditions, namely chronic bronchitis and emphysema that are seen in 
patients. According to American Lung Association, 12.7 million Americans have been 
diagnosed with COPD, while 24 million people have impaired lung function, considered 
as underdiagnosed for the disease resulting in a huge cost to the nation of about $50 billion. 
Emphysema is an airway disease in which inflammation mediated elastin damage occurs 
over a long period. Owing to protease/anti-protease imbalance caused by chronic 
inflammation, various “elastases” can degrade elastin. Loss of elastin in the lungs has been 
shown to correlate with loss of lung function in patients. Currently available treatments for 
COPD aim at only providing temporary relief to the patients by mitigating inflammation 
or by the action of bronchodilators. Elastin breakdown and chronic inflammatory 
conditions are hallmark of emphysema. We have developed unique way to deliver 
nanoparticles tagged with elastin antibody that recognizes degraded elastin in the 
cardiovascular disease sites. In this research, we have shown that this targeted delivery can 
be extended to emphysematous lungs to deliver doxycycline and pentagalloyl glucose 
(PGG) in an attempt to inhibit matrix metalloproteinase (MMP) activity and to preserve 
elastin in the lung tissue using both in vitro and in vivo approaches. 
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1 LITERATURE REVIEW 
1.1 The respiratory system  
Human respiratory system (Figure 1-1) is a fascinating blend of organs that 
facilitates one of the most important functions of the body, respiration. Anatomically, it is 
broadly divided into upper and lower respiratory tracts. Upper respiratory tract consists of 
nasal cavity, pharynx, and larynx while the lower respiratory tract forms the crux of 
respiratory system where the exchange of gases happens. Trachea, bronchi, and lungs form 
the lower respiratory tract. Gross anatomy of lungs shows us that the trachea splits into two 
large bronchi (right and left) which further divide into 23 generations of air ducts, the end 
 
Figure 1-1: Human Respiratory System 
(http://www.6aming.com/private/human-respiratory-system-
diagram-labeled/attachment/diagram-of-human-respiratory-system-
health-pinterest-inside-human-respiratory-system-diagram-labeled/) 
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of which forms the smallest functional units of lungs, called alveoli [2]. Alveoli interface 
with the surrounding capillaries to allow oxygen and carbon dioxide exchange. 
1.2 Composition of lung tissue 
Lungs are composed of cellular, vascular and extracellular tissue components. 
Epithelial cells provide continuous lining throughout the respiratory system. At the distal 
end of respiratory bronchioles, where they form alveoli, two types of alveolar cells (type I 
and II) start to appear. Type I cells are squamous epithelium, which provide thinnest blood-
air interface for exchange of gases, while type II cells form a part of alveolar septa and 
generate surfactant fluid. They also differentiate into type I cells to replenish them, which 
lack the ability to divide [3]. Alveolar macrophages form an important part of lungs’ 
cellular network, with a vital immunological role to play in clearance mechanism and also 
in pathological responses [4].  
Vasculature of lungs consists of bronchial and pulmonary circulations. Pulmonary 
circulation consists of pulmonary arteries bringing in the deoxygenated blood, which 
profusely divides into capillaries for gas exchange. Pulmonary veins transport back the 
oxygenated blood to the systemic circulation. Bronchial circulation intertwines with 
pulmonary circulation in a contrasting hemodynamic manner to supply blood to the lung 
tissue [5]. 
1.3 Lung physiology  
The lungs work to refresh the oxygen supply to the body. The left lung has two 
lobes owing to the presence of heart on left side while the right lung has three lobes. 
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Trachea divides into bronchi, which in turn divide into bronchioles and finally end up as 
alveoli. Alveoli are the places where gas exchange occurs from capillaries. On an average, 
our lungs have about half a liter of blood at any given point of time. The negative pressure 
acting on the alveoli makes sure no blood seeps into them except for very small amounts 
of fluid, which is safely taken back by the lymphatic system. The blood-air barrier at the 
point where capillaries pass alveoli forms the thinnest possible surface for gas diffusion 
into and out of capillaries.  
The lungs do this job of getting fresh oxygen in and spent carbon dioxide out by 
the process of respiration [5-10]. Respiration essentially consists of two tasks i.e. 
inspiration and expiration. The physiology of working of lungs involves its expansion and 
collapse during these tasks respectively. Primarily the diaphragm contracts to pull the lungs 
downwards and expand them. It relaxes to allow the lungs to contract. Secondary way of 
expanding and contracting lungs involves raising and lowering of the ribs involving 
intercostal muscles, scaleni, sternocleidomastoid, anterior serrati and abdominal recti 
muscles. 
The pressure of liquid in pleural space, called pleural pressure, is about -5 cm of 
water, which holds the lungs open at rest. The pressure inside alveoli, called alveolar 
pressure, remains very close to zero. During inspiration, the alveolar pressure falls slightly 
below atmospheric pressure and the pleural pressure goes down to -7.5 cm of water. This 
gives enough suction to draw 500 ml of fresh air. During expiration, the values go back in 
the same manner. The difference between alveolar and pleural pressures is called 
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transpulmonary pressure. The extent to which the lungs will expand for a unit increase in 
transpulmonary pressure is called the lung compliance. Lung compliance is the volume 
change that could be achieved in the lungs per unit pressure change. On an average the 
total compliance of both our lungs is about 200 ml of air per cm of water of transpulmonary 
pressure. The plot of pressure changes versus lung volume changes is called a compliance 
diagram and looks like a hysteresis curve (Figure 1-2). 
 
The compliance of the lungs comes from two factors i.e. (1) elastic forces of lung 
tissue and (2) elastic forces caused by surface tension of surfactant that lines inner walls of 
alveoli. Elastic forces in lung tissue come from mainly elastin and collagen network present 
in the interstitium. During inspiration, the elastic fibers are extended and owing to their 
action of hydrophobic interactions they tend to collapse thus pulling the lungs inwards and 
expelling the air. On the other hand, the surface tension of the fluid in alveoli tends to 
collapse the alveoli thereby creating a positive pressure to expel the air out. A type of 
 
Figure 1-2: Compliance diagram for lungs 
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protein called surfactant protein present in this fluid reduces its surface tension. This helps 
in creating a much less positive pressure with which the lungs expel the air, so that the 
inspiration doesn’t become a hard task. The pressure with which the alveoli expel the air 
can be calculated using the formula below.   
 
1.4 Lung volumes 
To know more about the functioning of lung, certain volumes can be measured at 
various points of respiration. There are four pulmonary volumes. Various capacities of 
lungs are defined as sum of two or more of the pulmonary volumes. These are listed in 
Table 1-1. 
A very good understanding of the functioning of normal lungs is important to 
appreciate the pathobiology of chronic obstructive pulmonary disease (COPD). In clinical 
settings, these parameters are used to assess the severity of the disease in a patient. In 
research involving animal models, evaluating the compliance, lung volumes, and capacities 
forms an important part of the experiment if investigating lung regeneration.  
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Table 1-1. Lung volumes and their average values in humans 
 Volume Definition Value (ml of air) 
1. Tidal volume (VT) Volume of air inspired or expired 
with normal breathing 
500 
2. Inspiratory Reserve 
Volume (IRV) 
Volume of air that can be inspired 
after tidal volume with full force. 
3000 
3. Expiratory Reserve 
Volume (ERV) 
Volume of air that can be expired 
forcefully apart from tidal volume 
1100 
4. Residual volume (RV) Volume of air that remains in the 
lungs after forceful expiration 
1200 
5. Inspiratory capacity 
(IC) 
Maximum amount of air a person 
can breathe after expiration 
IC = VT + IRV 
3500 
6. Functional Residual 
Capacity (FRC)  
Amount of air that remains in the 
lungs after a normal expiration 
FRC = ERV + RV 
2300 
7. Vital capacity (VC) Amount of air that a person can 
expel following a maximum 
inspiration and maximum expiration 
VC = IRV + VT + ERV 
4300 
8. Total Lung Capacity 
(TLC) 
Maximum volume to which the 
lungs can be expanded. 
TLC = IRV + VT + ERV + RV 
5800 
 
1.5  Lung disorders  
Chronic pulmonary disorders are broadly classified into restrictive and obstructive 
disorders based on how the lung function is hindered. In restrictive disorders like idiopathic 
pulmonary fibrosis, sarcoidosis, silicosis etc., patients have a trouble in inhaling to the full 
lung capacity. Their ability to fully expanding their lungs is restricted because of the 
stiffened interstitium. On the other hand, obstructive lung diseases like chronic obstructive 
pulmonary disease and asthma cause patients to exhale with difficulty because of the 
degraded extracellular matrix, which causes the airways to collapse [11]. 
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Chronic obstructive pulmonary disease is the third leading cause of death in U.S. 
following cancer and heart disease. In the year 2009, the number of people who died 
because of COPD is estimated to be about 134,000. According to the data published on 
“Trends in COPD” by American Lung Association in 2013, 12.7 million Americans have 
been diagnosed with COPD while a whopping 24 million people have impaired lung 
function, considered as underdiagnosed for the disease [12]. The devastating effect of the 
disease can not only be felt in the mortality rates but also in the projected economic burden. 
In 2010 it was projected approximately that the cost to the nation was $49.9 billion for 
COPD [12].   
According to the Global initiative for COPD, this disease is characterized by 
airflow limitation along with a range of pathological changes in the lung. COPD is an 
umbrella term encompassing two main pathological conditions chronic bronchitis and 
emphysema (Figure 1-3). These extreme conditions of COPD can exist either 
 
Figure 1-3: Graphical demonstration of chronic bronchitis and emphysema, the two 
pathological conditions of COPD. (http://www.livingwellwithcopd.com/en/what-is-
copd.html). 
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independently or together in a patient. In COPD associated condition emphysema, lung 
compliance is severely affected due to the irreversible damage that happens to the elasticity 
of lungs. Thus, they become less elastic and their compliance increases. Although COPD 
has been majorly linked to smoking as one of its major causative factors, recent 
advancements in research has made it possible to link genetic predisposition for the 
development of clinically significant disease [13-16]. The major genetic risk factor 
associated is the alpha-1 anti-trypsin (AAT) deficiency, which is a protease inhibitor of 
elastase. AAT deficiency is a rare recessive disorder in which patients have decreased 
levels of AAT [17]. Exposure to fine particulate matter in work environments and air 
pollution are considered other minor causes of emphysema [18, 19]. 
1.6 Symptoms and diagnosis 
Clinical symptoms of COPD include dyspnea, wheezing, cough and decreased 
expiration capacity. The volume of air that is expelled out at the end of exhalation is called 
Forced Vital Capacity (FVC) and the volume of air that is expelled in one second after 
complete inhalation is called Forced Expiratory Volume (FEV1). The ratio FEV1/FVC 
gives an estimate of the presence and severity of the disease, Table 1-2 [20-22].  
 
 
 
 
9 
 
Table 1-2- GOLD Guidelines for classification of air flow limitation in COPD 
In patients with FEV1/FVC less than 0.7 
GOLD 1 Mild FEV1>80% predicted 
GOLD 2 Moderate 50% < FEV1 < 80% predicted 
GOLD 3 Severe 30% < FEV1 < 50% predicted 
GOLD 4 Very Severe FEV1 < 30% predicted 
 
1.7 Emphysema: Molecular pathophysiology 
Currently accepted hypothesis about emphysema is that chronic exposure to 
cigarette smoke, particulate matter causes irritation in the alveoli, and this triggers an 
 
Figure 1-4: Schematic view of pathophysiological mechanism of emphysema 
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inflammatory response. This response attracts many types of inflammatory cells like 
macrophages, neutrophils and lymphocytes to the area. Cytokines, reactive oxygen species, 
prostaglandins, leukotrienes, proteases etc. released by these cells mediate the progression 
of the disease. This leads to a protease/anti-protease imbalance in the lungs, which causes 
the breakdown of elastin [23]. The pathology of emphysema consists of other changes. For 
example, lung fibroblasts change their phenotype [24], degradation products of elastin 
fibers act as chemoattractants to inflammatory cells [25], the inflammatory response shifts 
to chronic phase, alveoli tend to enlarge, small air ways constrict allowing less air to escape 
during exhalation and finally the irreparable loss of elastin network leaves macroscopically 
visible holes in the lungs [26]. Elastin in the lung is degraded by enzymes called 
“elastases”. A few members of serine (e.g. neutrophil elastase, pancreatic elastase), 
cysteine (Cathepsin K) and metalloproteinases (MMP-2, MMP-9 and MMP-12) can cleave 
elastin [27, 28]. In diseases like abdominal aortic aneurysms (AAA) and COPD factors like 
inflammation and oxidative damage initiate and aggravate the elastin degradation [29]. 
Elastin derived peptides can act as chemo-attractants to the inflammatory cells, and the 
vicious cycle of elastin degradation and disease progression continues (Figure 1-4).  
1.8 Oxidative stress in COPD  
Oxidative stress has been shown to exacerbate COPD [30]. Oxidative species like 
superoxide radical, hydrogen peroxide, carbonyl stress markers like nitrotyrosine and lipid 
peroxidation products like 8-isoprostane, 4-hydroxy 2-nonenal and malondialdehyde 
(MDA) have been found in COPD [31-33]. Intrinsic anti-oxidants like glutathione, ascorbic 
acid, tocopherol and uric acid in the lung try to keep these levels balanced. But in COPD 
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patients, carbonylation and nitration reduce the activity and expression of an important 
transcriptional co-repressor histone deacetylase 2 (HDAC2), which is essential for the 
suppression of activated inflammatory genes and the anti-inflammatory actions of 
corticosteroids [34, 35]. This contributes to the inflammation in airways in COPD [54 55]. 
It has also been found that increased oxidative stress can lead to the release of chemokines 
that can attract inflammatory cells like dendritic cells, monocytes, and lymphocytes, which 
in turn elevate the levels of interleukins IL-17 and -18 [36] [37]. Several therapies have 
been studied to combat oxidative stress (Figure 1-5). 
 
 
Figure 1-5: Anti-oxidant strategies based research in COPD [1]. 
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1.9 Elastin degradation and its importance 
Elastin is a remarkable protein present in the extracellular matrix (ECM) of our 
tissues. Its ability to render elastic properties to some vital tissues like arteries, skin and 
lungs marks the physiological importance of this fibrous protein. With a half-life period of 
74 years, majority of elastin deposition occurs during embryonic and childhood stages [38, 
39]. Elastin synthesis has been documented in fibroblasts, smooth muscle cells, 
chondrocytes and endothelial cells [40-43].  While most of the vertebrate aortic tissue 
consists of up to 50% of elastin, the amount of elastin in lungs differs across species. It can 
range from as low as 2% in rodents to about 28% in humans [44]. Elastin in the lungs 
appear as concentric circles in pulmonary arteries. As they reach the lowest level of 
organization, they appear as fine mesh in alveolar walls. 
Elastin is made up of elastic fibers that have two major components, one amorphous 
and one fibrillar (Figure 1-6). The extensively cross-linked elastin of the amorphous 
component 
comprises 90% of 
the fiber. The 
fibrillar component, 
is a collection of 
microfibrils, that are 
rich in acidic 
glycoproteins and is 
about 8-16 nm long 
 
Figure 1-6: TEM structure of elastic fiber 
Amorphous elastin
Microfibrils
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[45]. Many different proteins like fibrillins, microfibril associated glycoproteins-1 and 2 
(MAGPs-1 and -2), latent TGF-β binding protein (LTBP) and fibulins contribute the 
anchoring of elastin and provide it with a structural coating [46]. Fibrillin-1 largely makes 
up microfibrils in ECM that likely anchor the forming elastic fibers [47]. Lysyl oxidases 
(LOX) are a group of five enzymes including LOX, and LOXL 1-4, which cross-link 
tropoelastin and aid the process [48]. 
Elastin primary structure is mainly composed of hydrophobic amino acids like 
glycine and proline [49]. Characteristic peptide sequence repeats VPGVG and PGVGV are 
seen in the elastin protein [50]. Tropoelastin, is a 72kDa protein that is secreted from cells 
[51]. It has been shown in mice that elastin expression reaches the highest during postnatal 
days 0 to 14 and then decreases rapidly to remain likewise throughout the life [52]. Genetic 
mutations in the elastin gene have been shown to contribute to susceptibility of lung disease 
[53].  
Initially, tropoelastin gene is expressed by fibroblasts or vascular smooth muscle 
cells and then tropolelastin molecules are secreted into the ECM [54]. The tropoelastin 
molecules begin to accumulate on the surface on the cell to create 1-micron spherules. This 
accumulation of tropoelastin aids coacervation of tropoelastin molecules. Eventually the 
tropoelastin is oxidized by the lysyl oxidase enzymes and followed by aldol condensation 
and Schiff base reactions among lysyl residues to crosslink elastic fibers with desmosine 
and isodesmosine links. The microfibrils that exist in the ECM are transported to where 
the new elastin is being formed, by members of the fibulin protein family. The elastic fiber 
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produced as the final product is very stable and able to give human tissue the ability to 
stretch and recoil [53]. Smooth muscles cells (SMCs) and fetal lung fibroblasts go through 
a different process of binding to tropoelastin. SMCs, much like chondrocytes, use heparin 
sulfate chains through proteoglycans on the cells surface to bind to the tropoelastin. In the 
fetal lung, fibroblasts use heparan sulfate moiety and integrin αvβ3 receptors [55].  
Elastin binding protein (EBP), made of a 67-kDa peripheral subunit attached to two 
membrane bound proteins of 61 and 55 kDa, carries tropoelastin molecules to fiber 
formation sites on the surface of cells. Initially, tropoelastin binds to an EBP complex that 
is intact. The 67-kDa subunit loses its affinity for tropoelastin and the membrane bound 
 
 
Figure 1-7: Schematic representation of elastin synthesis and assembly by cells 
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protein when a sugar moiety binds to the EBP. The loss of affinity leads to tropoelastin 
being released onto growing elastic fibers [45]. The process of elastic fiber assembly is 
shown schematically in Figure 1-7. 
1.10 Elastin loss in COPD 
To perform the respiration task effectively, lungs need to be compliant enough. The 
compliance of the lungs comes from two factors, namely (1) elastic forces of lung tissue 
and (2) elastic forces caused by surface tension of surfactant that lines the inner walls of 
alveoli. Elastic forces in lung tissue come from mainly elastin and collagen network present 
in the interstitium. During inspiration, the elastic fibers are extended and owing to their 
elastic action they tend to collapse during exhalation, thus pulling the lungs inwards and 
expelling the air. In COPD associated condition emphysema, the irreversible damage that 
happens to elastin protein in lungs severely affects lung compliance. Loss of this elastin 
network causes alveoli to enlarge and decrease gas exchange capacity. Physiologically, the 
lungs lose their elastic recoil, which cannot be reversed fully. 
As we age, elastin gene expression decreases dramatically leading to no elastin 
production, so the tissues must rely on the elastin deposition that occurs in the womb and 
early in life [56].  In order to make elastin, tropoelastin molecules must interact and then 
crosslink, forming insoluble elastic fiber. The vital role that elastin degradation plays in 
the development and progression of COPD has been studied in many animal models [57, 
58]. 
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1.11 Elastin degradation as biomarker in COPD 
Elastin fibers have very little turn over. Degradation of such elastic fibers is seen in 
emphysema. As a result, elastin damage is used as a marker for this disease. It has been 
shown in COPD patients that less elastin is present in the distal lung parenchyma and small 
airways [59, 60]. Merrilees et al., have observed a positive correlation between elastin fiber 
fraction in the lungs and forced expiratory volume (FEV-1) [61]. Elastin degradation 
results in elastin derived peptides (EDPs), which have been shown to be chemoattractants 
for monocytes. Sellami et al., have even shown that intra-tracheal injection of VGVAPG 
amino acid (one of the EDP sequences) causes emphysema in a murine model [62]. He et 
al., have characterized about 40 peptides by digesting human lung samples with MMP-12 
and HNE and compared thus derived peptides with those detected in patients [63]. They 
have observed some of these peptides circulating in COPD patients while these were 
completely absent in normal subjects. 
1.12 Experimental models for studying emphysema 
Experimental models of COPD have helped us understand many aspects of 
pathophysiology of the disease as well as therapeutics’ effect on lungs. Models used for 
studying COPD can mainly be divided as in vitro, in vivo, and in silico models. Researchers 
have tried looking at the effect of various individual and combined stimulations on distinct 
type of cells that participate in the disease pathway by using in vitro models. On the other 
hand, animal models provided very powerful and insightful details on topics like 
pathophysiology of COPD and advancement of possible pharmacological treatments. In 
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silico models have looked at drug delivery simulations and identifying variables that can 
assist in diagnosing the disease better. 
In vitro models: In vitro models of COPD employ a chosen cell type to study the 
effects of one or more causative agents of the disease [64]. Culture of cells explanted from 
patients or immortalized cell lines have been used. Exposure of these cells to the 
inflammatory inputs have helped in understanding certain cellular mechanisms, which 
would not have been possible in a complex environment such as human disease or animal 
models of disease.  
Out of the known causes of COPD, chronic smoking is strongly linked to the 
decrease in forced expiratory volume of patients. Naturally, cigarette smoke extract (CSE) 
has been adopted mostly as a way of inducing inflammatory environment in cell cultures. 
CSE is nothing but a liquid (either cell culture medium or buffered saline) containing 
soluble components of cigarette smoke, obtained by bubbling the smoke directly into it. 
Such solution is then sterilized and added to cell cultures at desired concentrations. With a 
number of variables governing the preparation of CSE like the cigarettes used, medium for 
bubbling and type of cells to test CSE with, there appear many ways of utilizing this in 
vitro stimulant for studying COPD.  
 Nyunoya et al., have observed that single cigarette smoke extract dose inhibits lung 
fibroblast proliferation, while multiple exposures to cigarette smoke move cells into an 
irreversible state of senescence [65].  Nakamura et al., [66] have observed that treatment 
of human fetal lung fibroblasts with CSE inhibited proliferation and migration of the cells. 
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Hoshino et al., [67] have also observed similar derogatory effects of CSE on viability of 
A549 cell line, causing DNA fragmentation and increase in oxidative stress. They have 
also shed light on the protective effect of N-acetylcysteine (NAC) against CSE exposure. 
An earlier interesting finding by Laurent et al., shows that cigarette smoke extract blocks 
the crosslinking of tropoelastin molecules by inhibiting the function of lysyl oxidase [68]. 
Some of the findings from the literature are presented in Table 1-3. 
Table 1-3. Summary of CSE effects in various cell culture models.  
Cell type Effect of CSE Reference 
Fibroblast ↑Apoptosis [69] 
Fibroblast ↑Apoptosis, Oxidative stress↑ [70] 
Epithelial ↓Cell viability, Oxidative stress↑ [67] 
Fibroblast ↓ Cell proliferation and migration [66] 
Epithelial ↑ Epithelial to mesenchymal transition [71] 
Smooth muscle ↑ Proliferation via PKC-PDGFB signaling [72] 
Endothelial ↑Cell injury via JNK pathway [73] 
Fibroblast ↑Cellular senescence, ↓ Cell proliferation [65] 
Endothelial, Platelet ↓ Cellular viability, ↑Aggregation  potential [74] 
T cells, Epithelial 
↓ Cytotoxic activity of T cells, ↑IL-8 and 
MUC5AC 
[75] 
Dendritic 
↑PGE2 production, ↓DC-induced T-cell 
proliferation 
[76] 
Bronchial epithelial ↓ Chloride secretion, ↑Mucus secretion [77] 
Dermal fibroblast ↓Cell viability, Oxidative stress↑ [78] 
Alveolar macrophage ↑Apoptosis [79] 
Bronchial epithelial ↑DNA damage [80] 
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Other in vitro models include exposure of cells to non-tobacco irritants like fine 
particulate matter. Li et al., have previously observed that ultrafine particle exposure 
increases the permeability of epithelial cells using A549 cell line [81]. They have also 
observed decreasing glutathione levels, which acts as an antioxidant in the body. Lee et al., 
[82] have experimented with coal dust exposure on type II pneumocytes, which resulted in 
increased extracellular matrix proteins, regulated by tumor necrosis factor-α (TNF- α) and 
tissue growth factor-beta1 (TGF-β1). How cigarette smoke can act on lung cells is depicted 
in Figure 1-8.  
 
In vivo models: Animal models have contributed greatly towards the advancement 
of knowledge in COPD. There are many methods mentioned in literature that are used to 
induce COPD like changes in animal lungs [83-85]. Broadly, animal models of COPD can 
 
Figure 1-8: Effects of cigarette smoke on lung cells 
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be divided as cigarette smoke exposure, elastase instillation and genetic manipulation. 
Mice are the most commonly used animals for inducing COPD while rats are considered 
less susceptible to develop COPD[86]. 
Cigarette exposure: Exposure of animals to cigarette smoke is a classical model 
used by researchers owing to the fact that tobacco smoke is the most important risk factor 
of COPD. The advantages of such exposure include emphysematous changes to lungs, 
recruitment of inflammatory cells, and airway fibrosis similar to seen clinically in smokers. 
[87-89]. On the other hand, the exposure model usually requires long time to observe 
significant changes in the lung. Since there is no set standard on the type of cigarettes, 
dosage of cigarette smoke given to animals, and delivery systems used in this model, many 
studies have used their own methods [90-92]. Multitude of parameters such as, importance 
of inflammatory cells in progression of the disease and possible anti-inflammatory 
therapies have been studied in detail in mice, rats, guinea pigs, and dogs [93-99]. 
Elastase model: Elastases are enzymes that degrade elastin in the body. Thus it is 
no surprise that instillation of elastase emerged as one of the widely used and characterized 
models of emphysema in the animal setting. Porcine pancreatic elastase has been very 
popular agent used to damage lung structure in animals. The ease of use, quicker damage, 
and better optimization form the major advantages of the elastase model [91, 100]. 
However, the disadvantage of the elastase comes from its inability to comprehensively 
reproduce pathogenesis as seen in clinical findings [101]. Clearance of enzyme from lungs 
also dictates the extent of damage [102]. Studies reported in the literature differ in the 
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amount of elastase concentration used to damage the lungs of animals (rats, mice or 
hamsters), the amount of time allowed for damage and also the intervention of 
exacerbations like exercise and infections [103-108]. Most common observations of 
elastase challenge to lungs are enlargement of airspaces, inflammatory cell influx into the 
lungs, and increased lung compliance[109-112]. 
Genetic manipulation models: Aptly called as second generation models of COPD, 
genetically manipulated animals have been used to evaluate many key players in its 
pathogenesis [113]. Pallid mice, which have alpha-1 antitrypsin deficiency, are shown to 
develop a milder form of emphysema [114]. Beige mice also develop COPD-like lesions 
due to a defect in neutrophil granules [115]. Genetic models have also been useful to 
emphasize the importance of MMPs in the pathophysiology of emphysema. D’Armiento 
et al., have shown that expression of human collagenase gene in transgenic mice leads to 
alveolar wall disruption with no signs of inflammation or fibrosis [116]. Hautamaki et al., 
have used macrophage elastase (MMP-12) knock out mice in a cigarette smoke exposure 
model of emphysema. Their observations lead to the finding that mice lacking MMP-12 
fail to develop emphysema. [117]. 
Targeted mutagenesis has allowed to knock out specific proteins to evaluate their 
function in disease pathogenesis [57, 58, 118, 119]. Rangasamy et al. showed that 
disruption of the Nrf2 gene led to earlier onset and more extensive features of emphysema 
in mice exposed to cigarette smoke, stressing the importance of this gene [120]. Leco et 
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al., have observed spontaneous air space enlargement and impaired lung function when 
tissue inhibitor of metalloproteinases-3 (TIMP-3) has been knocked out [121]. 
Other animal models have employed a completely different variety of substances 
to achieve COPD like pathology in the lungs. These include instillation of nitrogen dioxide 
[122], lipopolysaccharide [123, 124] [125], cigarette smoke extract[126, 127], elastin 
fragments[128], cadmium[129], copper deficiency[130].  
1.13 Treatments 
Currently, there is no clear-cut treatment plan available for COPD. There are drugs 
available to provide temporary relief to patients and to treat the exacerbation of the disease. 
However, a long-term reliable treatment has not been found for COPD. Treatment of 
COPD with drugs used for asthma seems inappropriate, as the difference in inflammation 
is markedly different in both cases. Along with pharmacological treatments, smoking 
cessation is also advised in patients to curb the disease progression [131]. Pharmacological 
therapeutics for COPD treatment are divided based upon their course of action. 
Bronchodilators, mediator antagonists, anti-inflammatory agents and remodeling agents. 
Bronchodilators: Bronchodilators aim at providing relief to patients by relaxing 
muscles around airways and by clearing mucus for easier breathing. Depending on the time 
of their action, there are short, long and ultra-long acting bronchodilators (LABAs and 
ultra-LABAs), which can have effect up to 24 hours. Carmoteral, indacaterol, vilanterol 
are some of the examples of available bronchodilators [132]. Muscarinic antagonists are 
drugs that block activity of muscarinic responsive acetylcholine receptor. Acetylcholine 
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directly acts at muscarinic receptors on airway smooth muscle to cause bronchoconstriction 
[133]. Long acting muscarininc antagonists (LAMAs) like ipratropium bromide, 
tiotropium bromide [134], aclidinium bromide [135] have made their advance into the 
clinical treatment. Tiotropium bromide has been shown to be effective because of its anti-
inflammatory properties [136, 137]. 
Anti-Inflammatory drugs: The use of anti-inflammatory drugs is also a viable 
therapy as inflammation causes disease progression. Since corticosteroids have proven to 
be ineffective in reducing inflammation in COPD, new drugs like phosphodiesterase 4 
(PDE) inhibitors, TNF-α inhibitors, NF-kB inhibitors, p38 mitogen-activated protein 
(MAP) inhibitors, adhesion molecule inhibitors, PI-3 K inhibitors, anti-inflammatory 
cytokines, leukotriene B4 inhibitors, and chemokine inhibitors are being evaluated for their 
anti-inflammatory efficacies [138-142]. Since human neutrophils are largely involved in 
COPD, drugs trying to stop the recruitment of neutrophils have surfaced as a way of 
treatment. Leukotriene B4 (LTB4) is a potent chemoattractant of neutrophils and is 
increased in COPD patients [143]. In one study, mice lungs were challenged with 
lipopolysaccharide (LPS) and cigarette smoke solution and treated with inhalable powder 
of a flower Lonicera japonica. This treatment has shown to decrease TNF-α and IL-6 levels 
in bronchoalveolar fluid and the number of inflammatory cells in peripheral blood. In 
addition, authors have also reported that this treatment has induced recovery of elastin and 
collagen distribution, reduction of caspase-3 expression in lung tissues of COPD mice 
[144]. 
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MMP Inhibitors: Another approach to preseve elastin is to inhibit matrix 
metalloproteinases that are involved in degradation of elastin protein [145]. In a guinea pig 
study involving cigarette smoke exposure an MMP9/12 inhibitor AZ11557272 has 
ameliorated the emphysema conditions [146]. In a cigarette smoke exposure model of 
emphysema, mice treated with nebulized Ilomastat (MMP inhibitor) have been shown to 
have reduced macrophage levels, recruitment of neutrophils and also a reduction in air 
space enlargement [147]. In another study using a broad spectrum MMP inhibitor CP-
471,474, delayed the emphysema induced by cigarette smoke in guinea pigs[148]. But none 
of the previous research has neither evaluated elastin loss with such treatments nor aiming 
to target elastin specific therapy to improve the mechanical function of the lung. 
Elastase inhibitors: Another class of drugs that are being used in research are 
elastase inhibitors. Inhibiting human neutrophil elastase can be a direct treatment to prevent 
further deterioration of mechanical function of lungs. Many earlier studies have been 
documented with various elastase inhibitors in the past [149-152]. A study with succinyl-
alanyl-alanyl-prolyl-valine-chloromethyl ketone (CMK) in hamsters showed CMK 
protected against emphysema when instilled 1 hour before human neutrophil elastase 
instillation [153]. Pre-treatment of hamsters with FR901277, an elastase inhibitor has been 
reported to reduce lung functional parameters quasi-static compliance and vital capacity in 
a hamster model of elastase induced emphysema [154].  ZD0892, a synthetic serine elastase 
inhibitor, showed reduction in inflammation levels and desmosine levels were also returned 
to control values showing increased elastin content [155]. So far, Sivelestat sodium hydrate 
(ONO-5046) is the only HNE inhibitor that is in use, but its use is highly limited owing to 
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its organ toxicity and irreversible inhibition of human neutrophil elastase (HNE) [156-159]. 
In this perspective, a potential neutrophil elastase inhibitor can definitely have a key role 
in preserving elastin in lungs.  
Alpha-1 anti-trypsin deficiency (AATD) is a minor cause of emphysema. Its main 
role is maintaining a balance between protease and anti-protease activity by inhibiting the 
proteolytic enzymes like neutrophil elastase [160, 161]. In the absence of AAT, elastase 
activity increases and causes elastin breakdown in lungs. For people with AATD, delivery 
of this protein has been investigated as a possible option to ameliorate the lung 
physiological function. Purified alpha-1 anti-trypsin (AAT) can come from sources like 
plasma derived from healthy individuals and recombinant protein [162]. Prolastin is a 
pioneer product of purified AAT from serum of healthy individuals [163]. Early trials 
conducted in the late 1990s have all reported that patients who received Prolastin had lower 
mortality and reduced decline in lung function [164-166]. With the recent advances in gene 
delivery, it has been made possible to deliver AAT using this method using various viral 
vectors [167]. Murine model of cigarette smoke induced emphysema has shown 
improvement with the usage of inhaled recombinant AAT. When treated for 6 months, the 
animals showed 73% reduction in air space enlargement and also had lower neutrophil 
levels in the broncheoalveolar lavage fluid (BALF) [168]. Thus, delivery of AAT may be 
considered as a useful treatment for preserving elastin by inhibiting neutrophil elastase 
activity in patients with emphysema.  
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Besides the aforementioned treatments, some novel treatment strategies are being 
explored. Saluja et al., have reported the efficacy of low molecular weight lignins with 
respect to anti-elastase, anti-oxidative and anti-inflammatory activities [169]. Shigemura 
et al., reported amelioration of emphysema by gene transfection of hepatocyte growth 
factor in Sprague-Dawley rats subjected to elastase instillation [170]. Cruz et al., have 
documented protective effects of bone marrow derived mononuclear cell therapy in an 
elastase-induced model of emphysema [171]. In a different treatment approach, Lee et al., 
have investigated the effects of a herbal formula PM014 in a murine model and have 
observed that the protective agent used attenuated the increased accumulation of immune 
cells, TNF-α and IL-6 levels in BALF compared to control mice [172]. Bai et al., reported 
erythromycin improving the T-cell responses contributing to lower levels of IL-8 and TNF-
α in cigarette smoke induced lung inflammation [173].  
1.14 Drug delivery to lungs  
Drug delivery to lungs has been investigated for centuries. In India, the Ayurvedic 
practice of making inhalation of stramonium and hemp by pipe was developing but may 
even have had its origins earlier than the ancient Egyptian use of inhalers. The Ebers 
papyrus from ancient Egypt (1554 B.C.) describes how the breathless may be treated by 
the inhalation of the vapor of black henbane [174]. With recent advancements, instruments 
like metered dose inhalers and nebulizers have conquered the drug delivery through 
inhalation route to treat pulmonary diseases. With respect to the vehicle for drug delivery, 
solid lipid nanoparticles, liposomes, and polymers have long been exploited as an option 
for controlled drug delivery.  
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Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are nanosized aqueous suspensions made of 
primarily triglycerides and phospholipids [175]. Silva et al., have used quercetin loaded 
SLNs as an anti-oxidant and anti-inflammatory therapy for asthma [176]. In a study by 
Paranjpe et al., sildenafil loaded SLN was tested for its toxicological effects in heart and 
lung tissues [177]. Also, curcumin loaded stearic acid and lecithin based SLN was 
investigated as a treatment for asthma by Wang et al., [178]. Amikacin, an antibiotic, was 
used with cholesterol SLNs for treatment of lung infections. They observed that SLNs 
showed better lung deposition and lasted longer when administered using pulmonary route 
[179]. 
Liposomes 
Liposomes are another lipid-based vehicle used for drug delivery. In the treatment 
of pulmonary diseases Arikace® (Amikacin,Insmed, Monmouth Junction, NJ, USA) and 
Pulmaquin™ (ciprofloxacin, Aradigm Corp., Hayward, CA, USA) have advanced to 
clinical trials aiming at treating lung infections [180]. Liu et al., have demonstrated higher 
drug targeting efficiency of ciprofloxacin when delivered using phospholipid based 
liposomal formulation, as compared to ciprofloxacin solution alone [181]. Liposomes for 
delivery of other drugs like anti-oxidants, anti-inflammatory drugs have also been 
documented in the literature [182] [183]. 
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Polymeric nanoparticles 
Owing to the possibility of tailoring of physical, surface, and degradation 
characteristics, nanoparticles made of polymers like poly (lactic acid) (PLA), poly ethylene 
glycol (PEG) present themselves as lucrative options in pulmonary drug delivery. In a 
study by Gill et al., [184] paclitaxel loaded PEG micelles were used for drug delivery. They 
found better drug absorption and localization in the lungs compared to systemic delivery 
of commercially available taxol. In a study by Yoo et al., a novel anti-inflammatory 
compound, hydroxybenzyl alcohol (HBA) was delivered using polyoxalate (HPOX) 
nanoparticles. They observed attenuation in the inflammatory response by a decrease in the 
levels of pro-inflammatory cytokines in the ovalbumin induced asthma mice [185]. 
Nanoparticles also provide a wide array of targeted delivery opportunities [186], which can 
increase availability of drug and systemic effects of the same. Other drug delivery vehicles 
like dendrimers, magnetic nanoparticles, colloidal dispersions have also been characterized 
and used by researchers to deliver drugs [187, 188]. One interesting observation that relates 
to COPD is work by Sivadas et al., [189]. They developed micro particles based on alginate 
polymer and elastin. These micro particles respond to elastases which prove to be useful in 
COPD related applications.  
1.15 Barriers for drug development for COPD  
There are no drugs available to arrest early stage emphysema despite availability of 
many anti-inflammatory drugs. The attempt to develop a long-term treatment for 
emphysema encounters two major problems. First, as chronic bronchitis is seen to co-exist 
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with emphysema in COPD, the primary concern of the treatments available now is to 
provide a relief to patients with their breathing with bronchodilators [139]. The current 
therapeutic approach also aims to mitigate the inflammation using corticosteroids, 
phosphodiesterase-4 inhibitors like Theophylline, MAPK inhibitors (SD-282 ), inhibitors 
of PI3Kγ/δ  and even macrolide antibiotics like Azithromycin[190] [191]. It is important 
to understand that decreasing the inflammation does not necessarily compensate the lung 
capacity that has been lost in terms of elastic recoil. At this point in COPD research, the 
loss associated with the disease is permanent. The loss of elastin in the alveolar walls results 
in decreased surface area for gas exchange and thus cannot be repaired fully. Secondly, the 
general route of administration of drug for pulmonary applications is inhalation. Inhalation 
of either the drug alone or drug loaded carrier particles face a lot of challenges in delivering 
drug to lungs. Emphysema involves the loss of inter-alveolar septa, which likely decreases 
the pulmonary uptake of drug due to the available surface area reduction [192]. Obstructed 
airway physiology, mucus plugs in bronchi and bronchioles may lower the deposition of 
aerosolized drug in the diseased areas which reduces the therapeutic effect [193]. Even in 
normally functioning lungs, a drug that has been inhaled may get eliminated by one of the 
three processes viz. mucociliary or cough clearance to the gastrointestinal tract, by passive 
or active absorption into the capillary blood network, or by metabolism in the mucus or 
lung tissue. The fate of an inhaled particle depends on its size, anatomy of airways and 
ventilatory parameters [194]. Nanoparticle have recently been investigated as potential 
drug delivery systems to the lungs because of various advantages they offer [195]. In order 
to increase the specificity and availability of nanoparticles loaded with drugs, use of 
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monoclonal antibodies to specific biomolecules within the lungs has been suggested as a 
potential opportunity but has been poorly explored [186, 196]. There is a greater need for 
a highly effective drug-delivery method, which combines an active targeting formulation 
and consistent local release of a drug for enhanced therapeutic effect for COPD.  
1.16 Polyphenols as enzyme inhibitor, anti-oxidant, and elastin stabilizing agents 
Polyphenols are a large and varied family of natural substances. Polyphenols 
consist of a hydrophobic core surrounded by phenolic (-OH) groups on the exterior of the 
compound. They can also be divided into ligands, flavonoids, phenolic acids, and stilbenes 
based on the number of phenolic rings and their accompanying structural elements [197]. 
They are present in all vascular plants and are secondary metabolites. 
Pentagalloyl glucose (PGG), a derivative of tannic acid (TA) is a polyphenol found 
in green tea and wine [198]. PGG (Figure 1-9) is comprised of five identical ester linkages 
which involve the core sugar’s aliphatic hydroxyl groups. PGG’s alpha anomer is not 
common in nature, but PGG does have numerous isomers, as do the rest of gallotannins. 
All of these isomers have a molecular weight of 940 g/mol. What vary based on the 
different structures of the isomers are the biochemical properties, specifically the ability to 
precipitate proteins, susceptibility to hydrolysis, and chromatographic behavior.  While 
PGG is best known for its anti-oxidant properties, its elasto-regenerative properties have 
been demonstrated both in vivo and in vitro [199-201]. 
31 
 
Polyphenols possess many beneficial properties that allow us to consider them as a 
potential treatment option for COPD. Polyphenols have long been characterized with 
respect to their protein interactions and protein precipitating ability [202]. Isenburg et al., 
have found that PGG can stabilize elastin and protect elastin fiber from further damage. It 
binds to elastin by hydrophobic interactions and makes it resistant to degradation by 
elastases [200]. Sinha et al., have observed that polyphenols not only protect elastin from 
degradation but also increases insoluble elastin production in healthy and aneurysmal 
vascular smooth muscle cells in vitro as shown recently by us [203]. Recent studies on 
abdominal aortic aneurysm (AAA) model in rats have shown that systemic delivery of 
PGG loaded NPs can inhibit aneurysm formation and revert aorta back to normal size 
[204]. Jimenez et al., showed that polyphenols protect elastin from degradation in dermal 
fibroblast cultures [205]. Evidence of polyphenol affinity towards proline residues concurs 
on this observation [206]. In addition to protecting elastin, green tea polyphenols have also 
been shown to inhibit matrix metalloproteinase activity [207, 208]. Other polyphenols like 
 
Figure 1-9: Chemical structure of PGG 
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curcumin and xanthohumol have also been investigated along the lines of elastin 
stabilization, matrix metalloproteinase activity inhibition and even anti-inflammatory 
effects [209, 210]. 
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2 PROJECT RATIONALE AND SPECIFIC AIMS 
As described the first chapter, there have been many studies documented to 
understand the pathophysiological mechanisms of emphysema progression. Many 
therapies have been tested for stopping the progress of lung damage in animal models. 
These therapies include usage of inhaled corticosteroids, anti-inflammatories, leukotriene 
inhibitors, phosphodiesterase inhibitors, synthetic MMP inhibitors etc., in an effort to stop 
the progression of lung damage. Other studies have used carboxymethyl cysteine, N-
acetylcysteine, polyphenols like curcumin as preventive therapeutics, which successfully 
showed that prior treatment of lungs with such compounds could restrict lung parenchymal 
damage. However, none of the therapies target the preservation and regeneration of elastin 
as a treatment to reverse emphysema. Given the direct and easy route for the drug to reach 
lungs, researchers have concentrated mostly on inhalation therapeutics. While this remains 
an easier option, the airway pathology, patients’ ability in inhaling the drug and drug 
clearance mechanisms in lung play a key role in determining the therapeutic efficiency of 
the drug. Targeted drug delivery to lungs through systemic route has not been explored to 
the maximum extent. 
As shown earlier, one of the important cause of emphysema’s worsening is loss of 
elastin in lung alveoli. We believe stabilizing elastin and making it resistant to degradation 
can halt the progression of emphysema. Furthermore, if we can restore lost elastin by 
targeted therapy, we can even reverse the disease. We have shown that pentagalloyl glucose 
(PGG) binds to  elastin and inhibits its degradation by proteases [211] in cardiovascular 
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tissues. It binds to elastin by hydrophobic interactions and makes it resistant to degradation 
by elastases [200]. We have shown  that periadventitial administration of PGG inhibits the 
development and further progression of already developed AAA in calcium chloride injury 
rat model [211]. We have further shown in cell cultures that PGG not only protect elastin 
from degradation but it also increases insoluble elastin production in healthy and 
aneurysmal vascular smooth muscle cells [203]. Polyphenols including PGG, 
epigallocatechingallate (EGCG) and Catechin were shown to increase coacervation of 
tropoelastin and LOX activity and thus increase insoluble cross-linked elastin deposition. 
Additionally, polyphenol treatments also decreased cellular MMP-2 activity as detected by 
zymography. Recent studies from our lab on AAA model in rats have shown that systemic 
delivery of PGG loaded NPs can inhibit aneurysm formation and revert aorta back to 
normal size [204].  
Thus, we would like to first test if inhibition of MMP activity with targeted MMP 
inhibitor therapy can prevent emphysema development. Next we would like to test if 
targeted delivery of PGG to emphysematous lungs can prevent progression of emphysema. 
By stabilizing the elastin in lungs, the connective tissue damage can be controlled along 
with a possibility of restoring the elasticity. PGG not only stabilizes and regenerates elastin 
but it also inhibits MMPs. It is known for its anti-oxidant properties also. Thus, PGG can 
be considered as a multi-purpose drug. As the earliest marker of emphysema is elastin 
degradation in lungs, developing nanoparticles that can only target degraded elastin would 
be a superior approach. We further hypothesize that these targeted NPs will stay at the site 
of damage for longer time and release the drug in a controlled fashion. Such a strategy, 
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once developed, can be used for other lung disorders to deliver minimal doses of drugs 
right where they are needed. 
2.1 Innovation of current research 
Use of bronchodilators and a few anti-inflammatory drugs might help alleviate the 
difficulties experienced by patients but there have not been any successful long-term 
therapeutics. The innovation of this research comes from two new approaches. One is to 
develop a drug delivery strategy and specifically deliver it to damaged lungs there by 
allowing an increased drug availability and efficiency. This will greatly reduce drug dosage 
required which is critical when it comes to MMP inhibitors such as doxycycline. Secondly, 
the targeted delivery of a naturally occurring polyphenol PGG with nanoparticles will serve 
a dual-purpose of keeping inflammation and oxidative damage in check and allowing 
elastin regeneration in lung alveoli.  
 
SPECIFIC AIM 1:  To investigate whether elastin-antibody conjugated albumin 
nanoparticles can be targeted to emphysematous lungs.  
Approach: We use intra-tracheal injection of elastase to create emphysema in rats. We then 
perform initial targeting studies with DiR (1, 1-dioctadecyl-3, 3, 3, 3-
tetramethylindotricarbocyanine iodide) dye loaded bovine serum albumin (BSA) 
nanoparticles (NPs) that are conjugated with anti-elastin antibody. We study the targeting 
percentages in various organs; analyze the lungs at histological level to study parenchymal 
damage and elastin damage. 
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SPECIFIC AIM 2: To investigate whether targeted nanoparticles can deliver an 
active drug like doxycycline to lungs and prevent MMP activity and elastin 
degradation.  
Approach: First we optimize loading of doxycycline in BSA-NPs that are conjugated with 
anti-elastin antibody. We study drug loading efficiency, in vitro release, drug activity, and 
cellular uptake of NPs. NPs with optimum drug loading and release profile are then 
delivered intravenously in rats where lungs have been damaged using intra-tracheal 
elastase injection. We study the MMP activity from the BALF of rat lungs and compare 
them among control, nanoparticle and systemically treated groups. 
SPECIFIC AIM 3: To investigate whether PGG treatment can help pulmonary 
fibroblasts make more elastin while suppressing MMP activity in a cell culture model 
of emphysema  
Approach: We create emphysema-like inflammatory conditions by treating rat pulmonary 
fibroblasts in cell cultures with TNF-α and CSE. Elastin quantification, MMP activity in 
the medium, LOX activity quantification combined with gene expression studies of elastin 
and LOX is included in the experimental design to understand if PGG can increase elastin 
deposition. We then also look at the reactive oxygen species (ROS) in the cells exposed to 
TNF-α and CSE and anti-oxidant property of PGG treatment. 
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SPECIFIC AIM 4: To investigate whether PGG loaded NPs can be targeted to 
emphysematous lungs and whether they increase elastin matrix deposition, thus 
bringing back the elastic recoil of lungs.  
Approach: Here we create a mild emphysema by elastase challenge in mice. We investigate 
the progression of disease at different time points after treatment with PGG loaded NPs. 
We use FinePointe® Resistance and Compliance machine to track the changes in lungs’ 
mechanical properties, as a measure of disease progression or suppression. Histological 
analyses then serve as an aid to observe the elastin stabilization/regeneration in lungs. 
Finally, we also look at local MMP activity quantification to assess MMP inhibition in vivo 
by PGG nanoparticles.  
Each specific aim research is described in separate chapters below.  
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3 SPECIFIC AIM 1: TO INVESTIGATE WHETHER ELASTIN-ANTIBODY 
CONJUGATED ALBUMIN NANOPARTICLES CAN BE TARGETED TO 
EMPHYSEMATOUS LUNGS  
3.1 Introduction   
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death 
in U.S. following cancer and heart disease. Chronic smoking has been established as a 
major risk factor, while recent research unveiled a possible genetic predisposition factor 
that could be associated with the development of clinically significant disease [13-16]. 
Emphysema is one of the two chronic pathological conditions seen in COPD patients. 
Currently, the widely accepted hypothesis about emphysema is that chronic exposure to 
cigarette smoke and particulate matter causes irritation in the alveoli and this triggers an 
inflammatory response. This response attracts many types of inflammatory cells like 
macrophages, neutrophils, and lymphocytes. Cytokines, reactive oxygen species, 
prostaglandins, leukotrienes, proteases mediate the progression of the disease [212, 213].   
The most general route of drug delivery used for pulmonary applications is 
inhalation of drug. Due to the lack of active targeting drug delivery system, the drugs that 
are inhaled into the lungs become restricted in terms of their availability over time. Particles 
with a size of 5-10 microns get deposited in mouth and larger airways by impaction 
mechanism. Those with size of 1-5 microns are deposited in smaller bronchi and 1-3 
micron sized particles can go deeper up to bronchioles via sedimentation. Particles with 
size 0.5-1 micron get deposited in the alveoli [214-216]. Apart from size, factors like 
hydrophilicity/hydrophobicity of the drug, mucociliary clearance mechanisms, drug 
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metabolism in lungs dictate the fate of inhaled drug. Natural clearance mechanisms like 
coughing and phagocytosis can prevent the drug from reaching the alveoli. From 
emphysema point of view, where the elastin damage is present in the innermost structures 
of the lung, there is a need for more drug to be released locally to stabilize and regenerate 
the lost elastin.  
In this research aim, we have used the elastin degradation in emphysema to target 
our DiR drug loaded bovine serum albumin (BSA) nanoparticles (NPs) using anti-elastin 
antibody coating. This antibody coated nanoparticles target only damaged elastin, while 
sparing the healthy elastin in the body and stick to the targeted site for a longer period.  
3.2 Materials and Methods 
3.2.1 Preparation of DiR dye loaded BSA nanoparticles 
DiR dye (PromoCell GmbH, Heidelberg, Germany) loaded BSA (Seracare, Milford, MA) 
nanoparticles were prepared using desolvation method and conjugated to anti-elastin 
antibody (US Biological, MA, USA) for targeting purposes described previously [217-
220]. Briefly, 250 mg of BSA was dissolved in 4ml of DI water.  2.5 mg of DiR dye 
dissolved in acetone was added to BSA solution. The mixture was stirred for one hour at 
room temperature following the addition of glutaraldehyde (EM grade 70%, EMS, PA, 
USA) at a concentration of 42µg/mg BSA. The mixture was added dropwise to 24mlof 
ethanol while sonicating (Omni Ruptor 400 Ultrasonic Homogenizer, Omni International 
Inc, Kennesaw, GA). The mixture was sonicated on ice for 30 minutes. Thus obtained DiR-
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BSA NPs were separated by centrifugation at 10,000 rpm for 10 minutes and washed with 
water by resuspension.  
3.2.2 Tagging NPs with elastin antibody 
DiR-BSA NPs were PEGylated (mPEG-NHS, PEG succinimidyl ester, MW 2000) 
(Nanocs, New York, NY) by incubating 2.5mg of PEG with 10mg of nanoparticles at room 
temperature for one hour with gentle vortexing. The elastin antibody (United States 
Biological, Swampscott, MA) was thiolated using Traut’s reagent. 1 mg/ml of Traut’s 
Figure 3-1: Schematic diagram showing conjugation of elastin antibody to DiR-BSA NPs. 
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reagent prepared in HEPES buffer at pH 8.8. 10µg of elastin antibody was added to 34 µl 
of 1mg/ml Traut’s reagent and 400μl of HEPES buffer. The thiolation process was carried 
out at room temperature for 1 hour, followed by filtration through 30kDa MWCO filter at 
a centrifugation speed of 10000g for 1 min. Finally, the thiolated antibody and PEGylated 
NPs were combined and incubated on a rocker shaker overnight at 4°C, to obtain ELN-
DiR-BSA NPs. Control particles were tagged with the IgG (Sigma Aldrich, St. Louis, MO) 
antibody (IgG-DiR-BSA NPs). A schematic diagram of conjugating DiR-BSA NPs to 
elastin antibody is shown in Figure 3-1. 
3.2.3 In vitro nanoparticle uptake  
ELN-DiR-BSA NPs were tested for their uptake by cells in a cell culture setting. 
Rat alveolar macrophages, rat pulmonary fibroblasts and human vascular endothelial cells 
(HuVECs) were grown in 24-well cell culture plates and subsequently incubated with 
ELN-DIR-BSA NPs (1 mg/ml) at 37°C in 5% CO2 for 24 hours. Two different batches of 
NPs were prepared as controls for charge and particle size. One batch was prepared with a 
positive surface charge (POS-DiR-BSA NPs), and one batch was prepared with smaller 
particle size (SMA-DiR-BSA NPs).  Positive surface charge was created by coating the 
NPs with chitosan deacetylated [221], average low molecular weight (Sigma, St. Louis, 
MO). 6 µg glutaraldehyde per mg BSA was used to produce NPs with a smaller particle 
size. Cells were washed afterwards with sterile phosphate buffered saline (PBS) for a total 
of three washes. Cells were imaged using EVOS® XL Cell Imaging System to visualize 
NP uptake. 
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3.2.4 Targeted delivery of ELN-DiR-BSA NPs in vivo 
All animal studies were performed according to the approved protocols and were 
compliant with the rules and regulations of Clemson University’s Institutional Animal Care 
and Usage Committee (IACUC) at all times. To induce elastin damage and emphysema, 
one of the widely established models i.e., elastase model of emphysema was chosen. Six 
week old male Sprague- Dawley (SD) rats (n=7) were used for in vivo targeting study. Four 
of the rats were given 50U of porcine pancreatic elastase (PPE) (Elastin Products Company 
Inc., Owensville, MO) dissolved in 200ul of phosphate buffered saline (PBS) and filter 
sterilized via intra-tracheal instillation. Remaining three rats received same volume of PBS. 
The rats were then allowed to undergo damage over four weeks of time after which they 
were injected with DiR loaded nanoparticles via tail vein. Three elastase and saline rats 
received ELN-DiR-BSA NPs. One elastase injected rat received IgG-DiR-BSA NPs to 
eliminate the non-specific targeting variable. Twenty-four hours after injection of 
nanoparticles, rats were euthanized (Figure 3-2). 
 
Figure 3-2: Timeline graph of study involving targeted delivery of DiR-BSA NPs in rats. 
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3.2.5 Lung compliance measurement 
Lung compliance was measured manually, post-mortem. Briefly, the trachea was 
cannulated and tied off with suture. A known volume of air was delivered to inflate the 
lung and the pressure was recorded using a pneumotach. 
3.2.6 DiR signal measurement 
After lung compliance measurement lungs, liver, aorta, heart, kidneys and spleen 
were harvested to check for DiR signal. This was done by imaging each organ with IVIS® 
Lumina XR Imaging system (Caliper Life Sciences, Waltham, MA) set to 
excitation/emission of 745nm/790nm. Background signal was subtracted before analyzing 
the signal intensities from the organs. Bio-distribution of nanoparticles was calculated 
based on the equation below, 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐵𝑖𝑜𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 =
(
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛 𝑜𝑟𝑔𝑎𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
𝑇𝑜𝑡𝑎𝑙 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛 𝑎𝑙𝑙 𝑜𝑟𝑔𝑎𝑛𝑠 ℎ𝑎𝑟𝑣𝑒𝑡𝑒𝑑
)
𝐷𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑜𝑟𝑔𝑎𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
𝑋100%  
Then the lungs were perfusion fixed using neutral buffered formalin and stored for 
histological analysis. 
3.2.7 Histological analysis 
Sections from both right and left lungs were used in observing damage in lungs. 
Processed tissue samples were embedded in paraffin and sections of 5 μm thick were made 
from the sagittal face. Hemotoxylin and Eosin (H&E) staining was used to observe general 
structural characteristics and enlargement of alveoli. Verhoff’s Van Gieson (VVG) staining 
(Polysciences Inc., Warrinton, PA) was performed according to manufacturer’s protocol to 
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look at elastin damage in the alveolar walls of the tissue. Furthermore, perfusion fixed 
lungs were cut into small pieces and embedded in Richard-Allan Scientific™ Neg-50™ 
Frozen Section Medium (ThermoScientific, Waltham, MA). 5 μm sections were made with 
a cryostat and observed using a CY-7 filter cube with EVOS® XL Cell Imaging System. 
3.2.8 Statistical analysis 
All in vitro experiments were done in triplicates. For in vivo studies, three to four 
animals were used per group. Data were analyzed by one-way ANOVA followed by 
Tukey’s test or Dunnett’s test. Dunnett's procedure was used when comparing all other 
treatments to a reference and Tukey's was used for all pairwise comparison. The data are 
reported as the mean ± standard deviation. Results were considered to be significant with 
p≤0.05. 
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3.3 Results 
3.3.1 Nanoparticle uptake 
Nanoparticles were investigated for their uptake by cells in vitro. This included 
incubating cells with three different types of cells. Normal DiR-BSA NPs were not taken 
up by any of the three cell types since they possess negative charge on their surface. But 
positively charged (POS-DiR-BSA NPs) and small size NPs (SMA-DiR-BSA NPs) were 
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Figure 3-3: Nanoparticle uptake of DiR-BSA NPs. Normal NPs were not internalized by cells 
while POS-DiR-BSA NPs and SMA-DiR-BSA NPs were readily taken up. Purple-DiR 
nanoparticles imaged using Cy7 filter. Scale bars: A-G 400µm; H-I 100 µm. 
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readily taken up by all the cells (Figure 3-3). Alveolar macrophages seemed to exhibit more 
uptake compared to fibroblasts and endothelial cells.  
3.3.2 In vivo targeting study 
DiR-BSA NPs were tested for their specific damaged elastin targeting in vivo. Lung 
compliance between groups did not show a significant difference (data not shown) which 
indicated that there was no severe damage done to the lungs. This concurs with the 
observation that the elastase instilled rats did not experience labored breathing at the end 
of 4 weeks. Rats which received PBS showed no fluorescence signal in their lungs. On the 
other hand, elastase instilled rats’ lungs were full of DiR signal (Figure 3-4A). Aorta which 
acted as a positive control for elastin did not have any signal from the dye in both groups 
(Figure 3-4B).  
Figure 3-4: NP targeting to elastase damaged lungs. (A) Fluorescence images of 
saline and elastase instilled rat lungs. ELN-DiR-BSA NPs targeting to damaged 
elastin in the lungs was clearly seen in elastase group but absent in saline group. (B) 
Fluorescence images of saline and elastase instilled rat aortae. Aortae from both 
groups showed no signal confirming the targeting of nanoparticles. 
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Furthermore, the rat that received IgG coating to DiR-BSA NPs did not show any 
targeting in the lungs. Targeting percentage for organs harvested was calculated by 
normalizing the epifluorescence signal to average dry weight of the organ. Compared to 
control group elastase group lungs had about six and half times the signal captured 
(0.907±0.47% vs 6.06±2.14%) (Figure 3-5A). Liver, spleen and kidneys showed DiR 
signal in both the groups. Biodistribution of nanoparticles in these organs is shown in 
Figure 3-5B.  
 
3.3.3 Histology 
The damage in lungs was confirmed using H&E staining of histological sections. 
H&E stain showed areas of air space enlargement in the elastase group rats (Figure 3-6 A-
B). VVG staining for elastin revealed damaged elastin in the alveolar walls which could be 
seen as faded black fibers (Figure 3-6 C-D). Rat lung sections from elastase group showed 
Figure 3-5: Bar chart showing biodistribution of NPs (A) Bar chart showing nanoparticle targeting 
counts in saline and elastase treated rat lungs. (B) Bar chart showing distribution of nanoparticles in 
liver, kidneys and spleen in both groups. * represents significantly different from saline group. 
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ELN-DiR-BSA NPs presence in the alveoli when viewed using CY-7 filter. This also 
confirmed the targeting of nanoparticles to lungs (Figure 3-7). 
 
 
 
Figure 3-6: Histological examination of saline and elastase group rat lungs. (A) saline group rat 
lung showed no damage while elastase treated (B) rat lung showed air space enlargement (scale 
bar = 100 µm); (C) saline group rat lung showing no elastin damage while (D) elastase group 
rat lung showed loss of elastin along the alveolar walls (scale bar=20 µm). 
49 
 
 
3.4 Discussion 
Emphysema is responsible for damage of alveoli owing to the chronic inflammation 
in the lungs there by decreasing gas exchange capability of lungs. It also leads to the loss 
of elastin fibers that results in loss of elastic recoil of lungs making the alveoli collapse. 
This requires the patient to use greater force to exhale the air out. As for the available 
treatments are considered, they aim at providing relief to the patients by bronchodilation 
while new anti-inflammatory agents are being developed [222]. The most general route of 
administration of drugs for pulmonary applications is by inhalation. There are many 
advantages of this route like local delivery, availability of drug, needleless treatment etc. 
but at the same time it may not be suitable for people with diseases like emphysema owing 
to multiple factors. It has been shown that inspirational capacity of COPD patients is less 
Figure 3-7: Fluorescence images of ELN-DiR-BSA NPs (A) Fluorescence images of 
elastase group rat lung section showing ELN-DiR-BSA NPs (scale bar=200µm). (B) 
Enlarged version of A (scale bar=100µm). 
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than that of normal subjects which might have a role on drug deposition [223, 224]. Inhaled 
drug particles also have to survive phagocytosis by 12-14 alveolar macrophages which 
span each alveolus [225]. In silico models are increasingly being used to assess particle 
deposition profiles. One recent study has shown that, while modeling lobar distribution of 
particles,  differences do exist between normal and emphysematous mice with factors like 
airway collapse, smaller airways, particle transport through expiration may impact particle 
deposition [226]. There have been specifically tailored improvements to increase the 
bioavailability of the drug by overcoming each of these barriers but there still needs a lot 
of work to be done in attaining a reliable solution to these barriers [227].  
Thus, targeting lungs via a systemic route like intravenous administration of 
nanoparticles seems promising. Elastin damage is one of the characteristics observed at 
protein level in emphysema. Matured elastic fibers have amorphous elastin protein 
wrapped around by microfibrils and other proteins which stabilize them. Damaged elastin 
fibers lack these microfibrils covering them and have the amorphous elastin exposed to 
elastin degrading enzymes [228-232]. This distinction observed in elastin related diseases 
has been taken advantage of in preparing nanoparticles to target tissues that experience 
elastin loss as a part of their pathophysiology. Anti-elastin coated nanoparticles have shown 
successful targeting in experiments conducted before in our lab with abdominal aortic 
aneurysm induced rats [218, 220, 233]. Extending this targeting concept to emphysema is 
investigated in this paper. Matrix metalloproteinases, especially MMP 9 and MMP 12, have 
been shown to play a central role in extracellular matrix degradation and progression of 
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emphysema [234, 235] and their inhibition has shown protection against emphysema 
development in animal models [146, 236].  
We did not observe any significant changes in the lung compliance between the 
groups. There was also no difference observed between the mean linear intercept between 
the groups. This might be because of the dosage that has been administered to the rats (50U 
per animal). This is comparatively a low dosage administered to damage the lungs. Massaro 
et al., [237], while observing alveogenesis using retinoic acid also have used a relatively 
higher dosage of 2U/g body weight of male SD rats. From the works of Borzone et al., 
[238] and Corteling et al., [239] it could be noticed that rats are relatively resistant towards 
developing emphysema compared to mice and hamsters. Rubio et al., [240] have used 75IU 
of PPE  in Wistar rats to show the therapeutic effect of N-acetylcysteine in attenuating the 
lesions. This shows that selection of species and strain can be important in correlating the 
extent of damage that would be observed in the lungs. 
Our nanoparticles possessed required surface charge and size to not being 
phagocytosed by macrophages. They were also PEGylated to increase their circulation time 
in the body. Nanoparticle uptake study showed that due to the negative surface charge these 
nanoparticles avoid being phagocytosed by macrophages and also uptake by any other cells 
like fibroblasts and endothelial cells. This result was important in the sense that 
phagocytosis by alveolar macrophages is one of the clearance mechanisms adopted by the 
lungs to get rid of foreign particles. Normal DiR-BSA NPs escaped phagocytosis while 
positive charge and small size DiR-BSA NPs could be clearly seen as internalized by 
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alveolar macrophages. Cytotoxicity of doxycycline nanoparticles assessed using live dead 
assay showed no decrease in cell viability. As for the targeting, the significant DiR signal 
observed from elastase damaged lungs combined with the observation of aortae in the same 
rats being void of signal proved that the nanoparticles target only damaged elastin in lungs. 
Adding to this, cryosections of lung sections also showed DiR loaded nanoparticles 
attached to damaged parts of the alveoli. These targeting studies are in agreement with 
targeting of aorta in our previous works and could only further reinforce the specificity of 
these nanoparticles for damaged elastin. 
3.5 Conclusion 
In conclusion, by taking advantage of elastin damage that occurs in emphysema as a part 
of its pathological process, we have developed a novel bio-degradable polymeric 
nanoparticle system that targets specifically elastin damage in lungs. We have confirmed 
the targeting specificity of these particles using fluorescence imaging of organs and 
histological examination to locate nanoparticles. 
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4 SPECIFIC AIM 2: TO INVESTIGATE WHETHER TARGETED 
NANOPARTICLES CAN DELIVER ACTIVE DOXYCYCLINE TO LUNGS 
AND INHIBIT MMP ACTIVITY  
4.1 Introduction 
Emphysema results in poorly reversible airway obstruction due to the destruction 
of alveoli and elastin fibers in the lung [241, 242]. Loss of elastin in the lungs has been 
shown to be correlated to loss of lung function in patients [60, 243]. Currently available 
treatments for COPD aim at only providing temporary relief to the patients by mitigating 
inflammation or by the action of bronchodilators [139, 141, 142, 191]. Bronchodilators are 
the best available option which can relax the airway muscles and provide relief from 
exacerbations of the disease. Corticosteroids have been shown to have no anti-
inflammatory effect in COPD patients [190]. New treatments that have come into light 
[222]  include Phosphodiesterase 4 inhibitors like Theophylline [244, 245], Cilomilast, 
Roflumilast, Tetomilast [246-248], MAPK inhibitors (SD-282 [249]), inhibitors of 
PI3Kγ/δ [250] and even macrolide antibiotics like Azithromycin [251, 252]. Despite the 
plethora of drug delivery opportunities available, there is a greater need for a highly 
effective delivery method which combines an active targeting formulation and consistent 
local release of a drug for enhanced therapeutic effect. 
Matrix metalloproteinases (MMPs) have acquired a lot of attention in emphysema 
research with their key role of damaging elastin fibers, thus contributing to the enlargement 
of air spaces and loss of elastic recoil in the lungs [253]. Various MMP inhibitors can also 
be included in the new set of treatments that researchers are targeting to reduce 
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inflammation in the lungs [146, 148]. MMP inhibitors have proven to be useful in diseases 
like abdominal aortic aneurysm and cancer successfully [218, 254-256]. Use of MMP 
inhibitors in COPD has also been explored in animal models [147, 148]. Doxycycline is 
one such potential broad spectrum MMP inhibitor that is shown to reduce MMP activity in 
smooth muscle cells [257, 258]. But there is always the risk of over-targeting MMPs with 
the systemic delivery of these drugs [259]. So there needs to be a controlled and targeted 
release of drugs to achieve maximum therapeutic efficiency. 
In this aim, we investigated a novel method of drug delivery with a systemic 
injection of nanoparticles loaded with doxycycline. We took advantage of elastin damage 
in emphysema and tested our hypothesis that anti-elastin coated bovine serum albumin 
nanoparticles injected intravenously will target the lungs and with a consistent release of 
doxycycline over a period, will suppress MMP activity locally. 
4.2 Materials and Methods 
4.2.1 Preparation of Doxycycline loaded BSA nanoparticles (DOX-BSA NPs) 
Doxycycline hyclate (Sigma Aldrich, St. Louis, MO) loaded BSA nanoparticles 
were prepared using the procedure described here with modifications. Briefly, 25mg of 
doxycycline hyclate was dissolved along with 100mg of BSA in 2ml of water and allowed 
to stir at 500 rpm for 30mins. Following this 4ml of ethanol was added dropwise at a rate 
of 1ml/min using an automated dispenser, which makes the solution turbid. 50μl of 8% 
gluteraldehyde (40ug/mg BSA) was added to crosslink the albumin and the mixture was 
set to stir for 2 hours at room temperature. Resulting solution was spun at 14000 rpm for 
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10mins to separate thus formed nanoparticles. Nanoparticles were washed thrice with DI 
water before proceeding with anti-elastin conjugation. Table 4-1 shows different 
parameters optimized in obtaining the final working formulation of doxycycline 
nanoparticles. 
Table 4-1. Characterization of doxycycline loaded bovine serum albumin 
nanoparticles. 
 
4.2.2 Tagging NPs with elastin antibody 
DOX-BSA NPs were conjuaged with anti-elastin antibody using the procedure 
described in chapter 3. DOX-BSA NPs were PEGylated (mPEG-NHS, PEG succinimidyl 
ester, MW 2000) (Nanocs, New York, NY) by incubating 2.5mg of PEG with 10mg of 
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nanoparticles at room temperature for one hour. The elastin antibody (United States 
Biological, Swampscott, MA) was thiolated using Traut’s reagent. 1 mg/ml of Traut’s 
reagent prepared in HEPES buffer at pH 8.8. 10µg of elastin antibody was added to 34 µl 
of 1mg/ml Traut’s reagent and 400μl of HEPES buffer. The thiolation process was carried 
out at room temperature for 1 hour, followed by filtration through 30kDa MWCO filter at 
a centrifugation speed of 10000g for 1 min. Finally, the thiolated antibody and PEGylated 
NPs were combined and incubated on a rocker shaker overnight at 4°C, to obtain ELN-
DOX-BSA NPs. 
4.2.3 Characterization of doxycycline NPs 
Size and zeta potential: The size and zeta potential of DOX-BSA NPs was 
measured using 90Plus Particle Size Analyzer (Brookhaven Instruments Co, Holtsville, 
NY) with three runs performed per one sample batch. 1mg/ml solution of nanoparticles 
was used for measuring particle size. The size was also confirmed by scanning electron 
microscopy of nanoparticles.  
Encapsulation efficiency: The supernatant obtained from the washout was used to 
estimate the amount of free doxycycline. Absorbance at 273nm was measured using a UV 
spectrophotometer (BioTek Instruments Inc., Winooski, VT) and compared to a previously 
prepared standard curve. Percentage of total drug added that was encapsulated was 
calculated using the following equation, 
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𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 %
=   
(𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 − 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑤𝑎𝑠ℎ𝑜𝑢𝑡) ∗ 100
(𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑)
 
Yield: 5ml of 1N NaOH was added to freshly prepared nanoparticles and stirred 
for 36hrs to completely dissolve the bovine serum albumin. Then the absorbance of 
albumin was measured at 280nm (A280) to calculate the amount of BSA present in the 
nanoparticles. Nanoparticle yield was calculated as total weight of BSA and doxycycline 
present in nanoparticles over initial amounts added. 
𝑌𝑖𝑒𝑙𝑑 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒
=
(𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝑆𝐴 𝑖𝑛 𝑁𝑃𝑠 + 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑜𝑥𝑦𝑐𝑦𝑐𝑙𝑖𝑛𝑒 𝑖𝑛 𝑁𝑃𝑠) ∗ 100
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝑆𝐴 𝑎𝑛𝑑 𝑑𝑜𝑥𝑦𝑐𝑦𝑐𝑙𝑖𝑛𝑒 𝑎𝑑𝑑𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦
 
Loading: Percentage of loading of doxycycline in BSA nanoparticles is calculated 
using the following equation, 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 % =
(𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑜𝑥𝑦𝑐𝑦𝑐𝑙𝑖𝑛𝑒 𝑖𝑛 𝑁𝑃𝑠) ∗ 100
(𝑌𝑖𝑒𝑙𝑑 ∗ 𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝑆𝐴 𝑎𝑛𝑑 𝑑𝑜𝑥𝑦𝑐𝑦𝑐𝑙𝑖𝑛𝑒 𝑎𝑑𝑑𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦)
 
In vitro release profile: Freshly prepared DOX-BSA NPs were re-suspended in 
1ml of DI water and incubated at 37°C. At specific time points, the nanoparticles were 
spun and the supernatant was read at 273nm to measure the amount of doxycycline 
released.  
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4.2.4 Cell culture for cytotoxicity 
Rat primary pulmonary fibroblasts and alveolar macrophages were obtained from 
CellBiologics (Chicago, IL) and ATCC (Manassas, VA) respectively. Fibroblasts were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) (ScienCell, Carlsbad, CA) 
supplemented by 10% fetal bovine serum (FBS) (Sigma Aldrich, St. Louis, MO), 1% 
Pencillin-Streptomycin (Corning, Corning, NY) and 1% fibroblast growth substrate 
(ScienCell, Carlsbad, CA). Alveolar macrophages were grown in K-12 medium (ATCC, 
Manassas, VA) supplemented with 10% FBS and 1% Pencillin- Streptomycin. HuVECs 
(Life Technologies, Carlsbad, CA) were grown in endothelial cell medium (ECM) 
(ScienCell, Carlsbad, CA) supplemented with 10% FBS and 1% Penicillin-Streptomycin. 
Cells with passage numbers two to five are used for in vitro studies. 
4.2.5 In vitro cytotoxicity of Doxycycline NPs 
A standard live/dead assay was performed to measure the cytotoxicity of NPs. Rat 
pulmonary fibroblasts, rat alveolar macrophages and human vascular endothelial cells 
(HuVECs) were cultured with NPs for 24 hours (0.5mg/ml and 1mg/ml). A Live/Dead 
assay (PromoCell GmbH, Heidelberg, Germany) was performed according to the 
manufacturer’s protocol to confirm cell viability.  
4.2.6 Functional drug release from nanoparticles 
To confirm that the drug released from DOX-BSA NPs is functional in inhibiting 
MMP activity, a simple MMP inhibition assay was performed ex vivo. BALF from rat lungs 
was used as sample to quantify MMP activity. Uninhibited sample was used as positive 
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control while one set of samples were incubated with 50ng of doxycycline released from 
DOX-BSA NPs. MMP activity was quantified using internally quenched peptide substrates 
for MMPs 2&9 (Ex/Em= 280/360 nm, MMP Substrate III, Anaspec, CA) and MMP 12 
(Ex/Em = 325/393 nm, 390 MMP FRET Substrate V, Anaspec, CA). One milligram of the 
substrate was dissolved in 50 µl of DMSO, and the solution was diluted in 10 ml of 
development buffer (50 mM Tris Base, 5 mM CaCl22H2O, 200 mM NaCl, 0.02% brij 35). 
2 µl of the substrate stock solution and 2 µl of the extracted protein were mixed with 96 µl 
of the development buffer and incubated for one hour at 37°C. A fluorescent plate reader 
(BioTek Synergy, BioTek, Winooski, VT) was used to read endpoint florescence intensity. 
4.2.7 Targeted delivery of ELN-DOX-BSA NPs in vivo 
Six week old male Sprague-Dawley rats (n=10) were used for investigating the 
potential of doxycycline loaded nanoparticles in suppressing the MMP activity when 
administered systemically. As shown in timeline graph (Figure 4-1), all the rats received 
intra-tracheal instillation of PPE (50 U per animal). Three groups of animals were used to 
test the working of DOX-BSA NPs in comparison to the systemic injection of drug as an 
acute treatment option. Three rats did not receive any kind of treatment after elastase 
injection (Non-treated group); three rats received systemic injection of doxycycline 
Figure 4-1: Timeline graph for animal study for targeted delivery of DOX-BSA NPs in rats. 
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hyclate solution via tail vein (300 µg per rat dissolved in 200 µl DI water) three days after 
the elastase administration and continued to receive weekly injections from then onwards 
(Weekly IV group). Four rats received one-time systemic injection of ELN-DOX-BSA 
NPs (10 mg/kg of animal) via tail vein only once i.e., three days after elastase 
administration (DOX-BSA-NP group).  All the rats were euthanized after four weeks of 
treatment. After euthanasia, lungs of rats were cannulated and flushed with saline to obtain 
bronchoalveolar lavage fluid (BALF).  
4.2.8 Measurement of MMP activity in BALF 
MMP activity in BALF was measured using internally quenched peptide substrates 
for MMPs 2&9 (Ex/Em= 280/360 nm, MMP Substrate III, Anaspec, CA) and MMP 12 
(Ex/Em = 325/393 nm, 390 MMP FRET Substrate V, Anaspec, CA). One milligram of the 
substrate was dissolved in 50µl of DMSO, and the solution was diluted in 10ml of 
development buffer (50 mM Tris Base, 5 mM CaCl22H2O, 200 mM NaCl, 0.02% brij 35). 
2µl of the substrate stock solution and 2 µl of the extracted protein were mixed with 96µl 
of the development buffer and incubated for one hour at 37°C. A fluorescent plate reader 
was used to read endpoint florescence intensity. 
4.2.9 Immunofluorescence for elastin and MMP-9 
Immunofluorescence study was done on paraffin embedded rat lung sections to 
visualize MMP 9 present in the tissue, using standard protocol. Briefly, tissue sections were 
deparaffinized and heated in 1X citrate buffer (pH 6.0) (Millipore, Billerica, MA) for 30 
minutes for antigen retrieval. They were then cooled to room temperature and washed with 
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wash buffer thrice. 5% BSA solution was used to block the tissue to reduce non-specific 
binding. Sections were washed twice with PBS and thrice with wash buffer (Enzo Life 
Sciences Inc., Farmingdale, NY) to remove excess BSA. Then anti-MMP 9 tagged with 
CY-7 (Bioss Inc., Woburn, MA) was added to the sections at a concentration of 10 µg/ml 
and incubated overnight at 4°C on a shaker. After washing the sections were cover slipped 
with Vectashield (Vector Laboratories, Burlingame, CA) on them to preserve the 
fluorescence. 
4.2.10 In situ zymography 
To examine activity of MMPs in the lung tissue samples in situ zymography on 
histological sections was performed. Fluorescently labeled gelatin was used as substrate. 
Gelatinolytic activity was observed in Non-treated, weekly IV and DOX-BSA-NP group 
frozen lung sections (6 μm thick) using DQ-gelatin as a substrate (Life Technologies, IL). 
Cryostat sections of lungs were air-dried for 10 minutes.  One part of DQ-gelatin (1 mg/ml 
of DI water) was mixed with nine part of 1% agarose (Promega, WI.) in PBS containing 
DAPI (1 μg/ml) (Life Technologies, IL).  A drop of the mixture was added to each section 
and incubated in development buffer (50 mM Tris Base, 5 mM CaCl2.2H2O, 200 mM 
NaCl, 0.02% brij 35) overnight at 37⁰C. Images were captured using EVOS® XL cell 
imaging system. 
4.2.11 Reverse zymography 
Tissue inhibitors of matrix metalloproteinases (TIMPs) activity was analyzed in the 
tissue homogenate using reverse zymography. Resolving (15% polyacrylamide, 1mg/ml 
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gelatin supplemented with 20U of collagenase) and stacking (4% polyacrylamide with 1% 
sodium dodecyl sulphate (SDS)) gel solutions were prepared fresh for every assay. 10% 
Ammonium persulfate and TEMED were added to polymerize the gels and they were 
casted using Surecast® (Thermo Fisher, Waltham, MA) gel casting equipment. Equal 
protein for all samples was loaded per well along with pre-stained molecular weight 
standards (Precision Plus Protein Standard, Bio-Rad, Hercules, CA). After electrophoresis 
gels were washed in 2.5% Triton-PBS solution and then developed in buffer (50 mM Tris 
buffer, pH 7.5 containing 5 mM CaCl2, 200 mM NaCl, 0.02% brij-35) overnight at 37°C. 
Then gels were stained with Coommasie blue and destained to visualize the active MMP 
bands using UVP Geldoc It® (UVP, Upland, CA) imager. The bands were analyzed using 
GelQuant® software.  
4.2.12 Casein zymography 
Matrix metalloproteinase 12 (MMP-12) activity was analyzed in the tissue 
homogenate using casein zymography. Resolving (12% polyacrylamide, 1mg/ml casein 
supplemented) and stacking (4% polyacrylamide with 1% sodium dodecyl sulphate (SDS)) 
gel solutions were prepared and stored at 4°C. 10% Ammonium persulfate and TEMED 
were added to polymerize the gels and they were casted using Surecast® (Thermo Fisher, 
Waltham, MA) gel casting equipment. Since casein protein also forms bands around the 
same size (25kDa) as that of MMP-12, the casted gel was pre-run once at 90V for 1 hour 
to remove excess casein. Then equal protein for all samples was loaded per well along with 
pre-stained molecular weight standards (Precision Plus Protein Standard, Bio-Rad, 
Hercules, CA). Electrophoresis was carried out at 90V for 80-90 minutes. After 
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electrophoresis gels were washed in 2.5% Triton-PBS solution and then developed in 
buffer (50 mM Tris buffer, pH 7.5 containing 5 mM CaCl2, 200 mM NaCl, 0.02% brij-35) 
overnight at 37°C. Then gels were stained with Coommasie blue and destained to visualize 
the active MMP bands using UVP Geldoc It® (UVP, Upland, CA) imager. The bands were 
analyzed using GelQuant® software. 
4.3 Results 
4.3.1 DOX-BSA NPs characterization 
 DOX-BSA NPs were characterized based on their size, zeta potential, yield, 
loading and release of drug (Table 4-2). DOX-BSA NPs had an average size of 175±39.66 
nm. The average size of nanoparticles was also confirmed by SEM images taken (Figure 
4-2). Zeta potential of these particles was measured to be -59.8±4.67 mV. Amount of 
doxycycline in NPs was 7.1±0.709 mg corresponding to an encapsulation efficiency of 
32.74±6.3%. Amount of BSA converted into NPs was calculated by dissolving them in 1N 
NaOH. Absorbance values at 280nm measured BSA in NPs as 31.7±2.09 mg. Total 
nanoparticle yield was calculated by summing the amounts of doxycycline and BSA 
present in NPs, leading to a value of 34.71±3.54%. Loading percentage of doxycycline in 
NPs was calculated using the formula mentioned above and this was equal to 16.77±1.99%.  
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In vitro release of DOX-BSA NPs doxycycline from the nanoparticles was 
measured at different time points (Figure 4-3). In the first 24 and 48 hours 9.68±3.4% 
13±4.56% of the drug was released. Using the NPs injection dose per animal, loading 
percentage of doxycycline and targeting percentage of NPs to the lungs in the formula 
mentioned in methods section, the amount of drug that would be delivered at each time 
point to the lungs was calculated to be 2.85±1.31μg in 48 hours while the total drug released 
from NPs into the system was 1.24±0.57mg. Percentage of doxycycline released from BSA 
NPs steadily increased and reached 46±9.54% in four weeks. By this time the total amount 
of drug delivered to the lungs was 9.15±1.38μg. 
Figure 4-2: Scanning electron microscopy images of DOX-BSA NPs. 
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Table 4-2 Properties of DOX-BSA NPs 
Particle size 175±39.66 nm 
Zeta Potential -59.8±4.67 mV 
Yield percentage 34.71±3.54 % 
Loading percentage 16.77±1.99 % 
 
 
Figure 4-3: Release curve of doxycycline from DOX-BSA 
NPs 
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4.3.2 Cytotoxicity of DOX-BSA NPs 
DOX-BSA NPs were not found to be toxic to all the three types of cells tested for 
at 0.5mg/ml and 1mg/ml concentrations. Live dead assay of all the three types of cells 
showed no abnormalities in morphology and no dead cells (Figure 4-4). The cell viability 
was same as that of control group. On the other hand, ethanol group showed no cells. 
 
 
Figure 4-4: In vitro cytotoxicity and nanoparticle uptake by cells. Cell viability of DOX-BSA 
NPs as assessed by Live-Dead assay. Cell viability was observed for three different types of cells 
i.e., rat alveolar macrophages, rat pulmonary fibroblasts and human vascular endothelial cells, 
under four different conditions, i.e., control, 1mg/ml DOX-BSA NPs, 0.5mg/ml DOX-BSA NPs 
and ethanol (50% final concentration). Scale bar = 400 µm;  
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4.3.3 Functional drug release 
from nanoparticles 
MMP activity quantification 
from BALF of rats showed that 
doxycycline released from the 
nanoparticles is functional. MMP 2, 9 
and 12 activities were significantly 
suppressed by the released drug from 
nanoparticles as compared to the uninhibited sample as shown in Figure 4-5.  
 
4.3.4 Measurement of MMP activity in BALF  
To compare the 
broad spectrum MMP 
inhibitory effect of 
doxycycline when 
delivered through two 
mechanisms, systemic and 
targeted, MMP activity in 
the BALF was measured 
using specific FRET 
substrates for MMPs 2&9 
Figure 4-5: Bar chart showing MMP activity 
suppression by doxycycline released from 
nanoparticles * represents significantly different 
(p<0.05). Dashed line represents uninhibited 
sample. 
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Figure 4-6: MMP activity in the BALF measured using specific 
FRET substrates for MMPs 2, 9 and 12, * represents 
significantly different from non-treated group (n=4 for DOX-
BSA-NP group; p<0.05) 
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and MMP-12. Weekly IV doxycycline group showed very high MMP 2,9,12 activities. 
Dox NP group showed a significant reduction in MMP activities (Figure 4-6). 
4.3.5 Immunofluorescence to visualize MMP-9 
To confirm the inhibition of MMPs by doxycycline an immunofluorescence 
imaging was performed on lung sections of all groups, as described above. MMPs were 
almost completely not seen in the groups treated by nanoparticles and acute systemic 
treatment with doxycycline (Figure 4-7).  
 
4.3.6 In situ zymography 
In situ zymography is used to detect active MMPs in histological sections. When 
the intensity of fluorescence was compared between weekly IV drug only injection and 
DOX-NP groups, we observed a significant suppression of signal from DOX NP group’s 
lung section compared to the IV drug injection (Figure 4-8). Non-treated group also 
showed similar MMP activity signal on par with Weekly IV group. This reduced MMP 
Figure 4-7: Immunofluoroscence assay for MMP 9 in (A) Non-treated group, (B) 
Weekly IV group and (C) DOX-BSA-NP group. Purple corresponds to MMP 9. Scale 
bar=400 µm. 
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activity concurred with the FRET assay results showing that one nanoparticle injection can 
suppress MMP activity for an extended period of time. 
 
4.3.7 Reverse zymography 
Reverse zymography of control, non-treated and DOX-BSA-NP group samples 
showed different TIMP activities. DOX-BSA-NP group showed less TIMP activity while 
the other two groups showed relatively more intense bands on the gel. This could be 
thought as a possible feedback mechanism by which reduction of MMP activity in the lungs 
by the released doxycycline might have caused the TIMPs to become not active. On the 
other hand, Non-treated group showed more TIMP activity to check MMP activity in the 
lungs. 
Figure 4-8: In situ zymography of frozen lung sections from non-treated, Weekly IV and 
DOX-BSA-NP group rat lungs. Fluorescence due to MMP 2 & 9 mediated breaking down 
gelatin can be seen in Weekly IV group (green) but reduced in DOX-BSA-NP group. 
Nuclei are stained with DAPI (blue). Scale bar = 200 µm. 
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4.3.8 Casein zymography 
Analysis of casein zymography gels showed that MMP-12 activity is significantly 
higher in the non-treated group while DOX-BSA-NP group has significantly reduced 
MMP-12 activity. Controlled release of doxycycline from the nanoparticles helps keep the 
activity of MMP-12 low in the lungs (Figure 4-9). This result is in concordance with FRET 
assay we used above for quantifying MMP activities. 
 
Figure 4-9: Casein zymography images showing MMP-12 
activity in Weekly IV and DOX NP groups. Below is a bar chart 
of densitometry analysis of MMP-12 activity bands quantified 
using GelQuant software. * represents significantly different 
from non-treated group. 
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4.4 Discussion 
Matrix metalloproteinases are proteases that degrade a variety of substrates. Owing 
to protease-antiprotease imbalance in emphysema, the role of these enzymes in degrading 
elastin and other ECM proteins has been exemplified using many studies. Inhibition of 
MMP activity in the lungs can lead to slowing down of lung damage that occurs in 
emphysema. MMPs, especially MMP 12, play a central role in ECM degradation and 
progression of emphysema [234, 235] and their inhibition has shown protection against 
emphysema development in animal models [146, 236]. Churg et al. further stressed the 
importance of MMP-12 in cigarette smoke model of emphysema by showing reduced 
levels of this protein produced by alveolar macrophages when treated with α-1 anti-trypsin 
[260]. Using our novel targeted drug delivery method, we investigated if a functional 
doxycycline can be delivered to inhibit MMPs in elastase challenged rat lungs. Our aim 
was to specifically deliver a broad spectrum MMP inhibitor like doxycycline, encapsulated 
in a bio-degradable nanoparticle system, to curb MMP activity. Doxycycline is a potent 
inhibitor of MMPs especially MMP 8 and 9 [261-263]. Doxycycline has been previously 
shown to reduce the severity of abdominal aortic aneurysms (AAAs) in various animal 
models. Manning et al., [264] have shown reduction of AAA formation in Ang-II murine 
model of the disease. Their study results also coincide with Uitto et al., [265] who also 
report decreased MMP 2 activity and also decreased MMP 2 gene expression in epithelial 
cell cultures. Petrinec et al., [266] have observed decreased local MMP 9 production in the 
abdominal aorta which led to the preservation of elastic matrix in the rats treated with 
doxycycline injections daily. We have synthesized DOX-BSA-NPs and characterized them 
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based on their yield, size, zeta potential, drug release and loading properties. Cytotoxicity 
of doxycycline nanoparticles assessed using live dead assay showed no decrease in cell 
viability at two different concentrations. These concentrations were very less compared to 
that delivered to the animal (10mg/kg animal). 
BALF is a key indicator of inflammation that is going on in lungs. Measurement of 
MMP activity from BALF evaluated the efficacy of nanoparticles in delivering functional 
doxycycline to the lungs. Non-treated rats without any drug treatment showed high MMP 
activity in BALF. This level of activity was similar to rats receiving weekly injections of 
doxycycline, clearly showing drug alone was inefficient in inhibiting lung MMPs. We 
show that targeting of nanoparticles to damaged elastin in the lungs and a controlled release 
of doxycycline played an important role in keeping down the MMP activity levels in rats 
that received single DOX-BSA NPs injection. An obvious advantage of such treatment is 
requirement of lower dosages.  
Dalvi et al., [267] have reported significant improvement in lung functions when 
moderate to severe COPD patients were treated with doxycycline (100 mg per day). In 
another recent pilot study Bhattacharya et al., [268] have observed pulmonary function 
improvements with doxycycline treatment (100 mg per day) compared to standard 
pharmacotherapy. In animal models, Rossiter et al., [269] have showed VEGF LoxP mice 
instilled through the trachea with an adeno-associated virus expressing Cre recombinase 
had reduced mean linear intercept values with continuous doxycycline treatment along with 
reduction in MMPs. Sochor et al., [270] have demonstrated MMP-9 inhibition and thus 
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pancreatitis-associated lung injury in rats with doxycycline treatment (30 mg/kg). 
Doroszko et al., [271] have reported MMP 9 inhibition by doxycycline (2 mg/kg) in 
mechanical ventilation-induced lung injury in Wistar rats. These experiments lasted for 
less than one day. On a similar scale, the average amount doxycycline released into the 
body of each rat in 24 hours is 0.163 mg/kg in our current study. This corresponds up to 
~180 and ~12-fold decrease in the amount of drug required for MMP inhibition with 
targeted delivery compared to Sochor et al., and Doroszko et al., results respectively.  
Doxycycline is used as an example in this paper to pave the way for many other drugs that 
can be targeted to lungs by our novel NPs. The reduced dosage using targeted delivery can 
be particularly useful when toxic drugs have to be delivered for treatment of diseases like 
lung cancers. 
4.5 Conclusion 
In conclusion, by taking advantage of elastin damage that occurs in emphysema as a part 
of its pathological process, we have developed a novel bio-degradable polymeric 
nanoparticle system that targets specifically lungs. We have confirmed the targeting 
specificity of these particles. Doxycycline loaded BSA NPs were optimized in their size, 
surface properties, yield, drug loading and release properties. Targeted delivery of 
doxycycline nanoparticles have led to significant inhibition of MMPs in the lungs. This 
opens up a promising way of controlling inflammation in emphysema there by stopping 
further damage to the lungs. 
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5 SPECIFIC AIM 3: TO INVESTIGATE WHETHER PGG TREATMENT CAN 
HELP PULMONARY FIBROBLASTS MAKE MORE ELASTIN WHILE 
SUPPRESSING MMP ACTIVITY IN A CELL CULTURE MODEL OF 
EMPHYSEMA  
5.1 Introduction 
Inability to restore lost elastin from the lungs poses a serious hurdle in halting the 
progression of emphysema in patients. In COPD patients less elastin is shown to be present 
in the distal lung parenchyma and small airways [59, 60]. Moreover, elastin degradation 
results in elastin derived peptides (EDPs), which act as chemoattractants for monocytes 
and other inflammatory cells [272]. Severe COPD patients have shown increased elastin 
mRNA production in their lungs but without a functional elastin increase [273]. It has also 
been shown that fibroblasts, which are major players in elastin production in lungs, switch 
to a pro-inflammatory phenotype [274]. Elastin regeneration requires coordinated 
expression of all molecules that help in the process, which does not happen in adults. 
Supporting this view, LOX and LOXL expression levels have been shown to decrease with 
age[275] [46].  
Participating in the protease-antiprotease imbalance in emphysematous lungs, 
MMPs have recently occupied a key position in remodeling of the ECM. Many varieties 
of MMPs have now been discovered, with MMP 12 followed by MMP 9 more pronounced 
in emphysema as they can degrade elastin and collagen in lung connective tissue [28, 145]. 
Their importance in emphysema has been documented in many studies [117, 146]. 
75 
 
Pentagalloyl glucose (PGG) is a derivative of tannic acid (TA) found in green tea, 
red wine, etc. We have previously shown from in vitro and in vivo experiments that PGG 
can preserve elastin, inhibit MMP activity and also help restore lost elastin in aneurysmal 
aorta of rats [203, 204, 276]. We hypothesize that PGG treatment to emphysematous lungs 
can be a multifaceted solution for treating this challenging disease. Given its anti-oxidant 
and anti-inflammatory properties combined with its affinity to bind to elastin, it can not 
only render elastin resistant to degradation, but it can also help in the formation of new 
elastin [198, 277]. In this aim, we investigated the effects of PGG on rat pulmonary 
fibroblasts in vitro, in terms of elastin production, elastin deposition in the ECM, inhibition 
of MMP activity, and its remarkable anti-oxidant effects in two different in vitro conditions 
mimicking emphysema. 
5.2 Materials and methods 
5.2.1 Preparation of cigarette smoke extract (CSE) 
Cigarette smoke extract was prepared using a custom designed instrument. Smoke 
from commercially available Marlboro® 100’s cigarettes (with filter) was passed through 
warm PBS. This column length was about 10 cm in length and the time taken to burn one 
cigarette was maintained at 5 minutes by adjusting the flow of air. Each cigarette was burnt 
until there was 2 mm left before reaching the filter. Smoke extract obtained by bubbling 
smoke from two cigarettes in 10 ml of PBS was considered a 100% concentrated solution. 
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5.2.2 Pulmonary fibroblast cell culture 
Primary rat pulmonary fibroblasts (Cell Biologics Inc©, IL, USA) were grown in 
Dulbecco’s Modified Eagle Medium (DMEM), (ScienCell™, CA, USA) supplemented 
with 10% fetal calf serum (FCS) (Sigma-Aldrich®, St. Louis, MO), 1% fibroblast growth 
substrate (ScienCell™, CA, USA), and 1% Penicillin-Streptomycin. Cells from passages 
2-6 only were used for all experiments. For all experiments, cells were allowed to grow for 
one day in normal growth medium before treatment with other compounds. 
5.2.3 FASTIN assay 
Total insoluble elastin deposited in the cell layers and soluble tropoelastin in the 
media were quantified using the Fastin™ Elastin assay kit (Biocolor, UK) according to the 
manufacturer’s protocol. Matrix elastin was normalized to total lysate protein released by 
the cells, which is assumed to be directly proportional to the total cell count, while the 
tropoelastin in medium was normalized to the total protein content in the medium. 
5.2.4 PGG concentration characterization 
To first optimize the concentration of PGG that should be added to cell cultures, 
cells were grown in 2, 5 and 10 µg/ml final concentrations (n=3 per group) of PGG 
dissolved in dimethyl sulfoxide (DMSO). The control group for this experiment had an 
equal volume of DMSO added to the cells. The volume of DMSO was kept at 0.05% final 
concentration of the total volume of the cell medium in the well plates. Cell viability was 
assessed using a Live/Deadassay and Picogreen® dsDNA (Life Technologies, Carlsbad, 
CA) assay. Elastin deposited in cell cultures was quantified using the FASTIN™ Elastin 
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assay kit (Biocolor, UK) as per manufacturer’s protocol. Results were normalized to the 
average of control group. 
5.2.5 Cigarette smoke extract characterization 
To determine the optimum concentration of CSE that should be added to cell 
cultures, cells were grown in different final concentrations of CSE viz. 0%, 1%, 5%, 10%, 
20% and 50%. A Picogreen® dsDNA assay along with a Live/Dead assay were used to 
calculate the cell viability under the above stated conditions. 
5.2.6 In vitro emphysema model 
To mimic emphysematous conditions in vitro, cells were treated with tumor 
necrosis factor (TNF-α) (Peprotech Inc. ®, Rocky Hill, NJ) and CSE. Cells were divided 
into six groups depending on the combination of substances they were treated with. The 
groups were: DMEM (DMEM only), PGG (10 µg/ml), tumor necrosis factor (TNF-α) (50 
ng/ml), TNF-α (50 ng/ml) + PGG (10 µg/ml), CSE (5% final concentration), and CSE (5%) 
+ PGG (10ug/ml). The same terminology has been used all throughout the paper for 
discussing the results obtained. Cells were grown under these conditions for up to 21 days, 
and the medium was replenished twice every week. The cell cultures were analyzed at days 
7, 14 and 21 for total protein, total elastin in matrix and medium, collagen in matrix and 
medium, and MMP activity in the medium. 
5.2.7 mRNA extraction and RT-PCR 
Cells grown in the aforementioned conditions were lysed at weeks 1 and 2, and 
mRNA from the cells was extracted using RNeasy RNA extraction kit (Qiagen, Valencia, 
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CA) as per the manufacturer’s protocol. The quality of the mRNA extracted was confirmed 
with the A260/A280 ratio as measured by a BioTek Synergy 2 plate reader (BioTek, 
Winooski, VT). Primers were designed for obtaining cDNA copies of Lysyl Oxidase 
(LOX), Lysyl Oxidase 1(LOXL1), Beta-2 Microglobulin (B2MG) (a housekeeping gene) 
and Elastin (ELN) genes with the sequences shown in Table 5-1 and obtained from 
Integrated DNA Technologies® (Coralville, IA). Reverse transcriptase polymerase chain 
reaction (RT-PCR) was performed in the following steps: 5 minutes at 25˚C, 60 minutes at 
42˚C, and 10 minutes at 72˚C using Oligo dT primers from a RT-PCR kit (Promega, 
Madison, WI) using a Mastercycler® Gradient PCR machine (Eppendorf, Hauppauge, 
NY).  
Table 5-1. Primer sequences and amplicon sizes for genes of interest 
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5.2.8 Quantitative PCR 
PCR amplification of cDNA was performed in the following sequence: 1 minute at 
95˚C, 30 seconds at 55˚C, and 40 seconds at 72˚C for 42 cycles. The qPCR was performed 
and analyzed using a Rotorgene qPCR machine (Qiagen, Valencia, CA). Gene expression 
in each sample was normalized to the expression of B2MG and compared to the DMEM 
group using the 2- (ΔΔT) CT method as follows: 
ΔΔCt = (Ct Target gene - Ct Reference gene) Experimental – (Ct Target gene - Ct Reference gene) Control 
5.2.9 Protein isolation 
A separate set of cell culture plates was used for quantification of elastin deposited 
in the cultures and in the medium. At the determined time points as stated above, the 
medium was collected from cultures and stored. Cells were washed with PBS, and 1 ml of 
1% Triton 100X (ThermoFisher Scientific, Waltham, MA) in PBS was added to each well. 
The well plates were sonicated for 30 minutes to lyse the cells and then the cell layer was 
scraped off using a rubber policeman. These lysed cells were centrifuged at 10000 rpm for 
10 minutes to collect the supernatant, which contained the lysate protein. The remaining 
cell pellet was used to quantify matrix elastin. Protein from both the lysate and the medium 
collected was measured using a bicinchoninic acid (BCA) protein assay (Pierce, Rockford, 
IL) as per the manufactures protocol. 
5.2.10 Gelatin zymography and Reverse zymography 
Active MMP activity was analyzed in the medium collected from cell cultures using 
gelatin zymography. Resolving (10% polyacrylamide with 1 mg/ml gelatin) and stacking 
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(4% polyacrylamide with 1% sodium dodecyl sulphate (SDS)) gel solutions were prepared 
fresh for every assay. 10% ammonium persulfate and TEMED (Thermo Fisher Scientific, 
Waltham, MA) were added to polymerize the gels, and they were cast using Surecast 
(Thermo Fisher Scientific, Waltham, MA) gel casting equipment. For all samples, 125μg 
of total protein was loaded per well along with pre-stained molecular weight standards 
(Precision Plus Protein Standard, Bio-Rad, Hercules, CA). Samples were electrophoresed 
for 90mins at 90V. After electrophoresis, the gels were washed in 2.5% Triton-PBS 
solution and then developed in buffer (50 mM Tris buffer, pH 7.5 containing 5 mM CaCl2, 
200 mM NaCl, and 0.02% brij-35) overnight at 37°C. Gels were then stained (Coommassie 
Blue 0.5%, methanol 40%, and glacial acetic acid 10% in DI water) and destained 
(methanol 40%, glacial acetic acid 10% in DI water) to visualize the active MMP bands 
using a Geldoc It® (UVP LLC, Upland, CA) imager. The bands were analyzed using 
GelQuant© software. Reverse zymography was performed in a similar fashion but with a 
different gel composition to visualize tissue inhibitor of metalloproteinases (TIMP) activity 
in the samples. 15% polyacrylamide gel was prepared with 1 mg/ml gelatin and 
supplemented with 20U of type II collagenase. A separate part of the gel with the same 
samples was incubated in development buffer along with PGG (20µg/ml) for both gelatin 
zymography and reverse zymography to observe if PGG can inhibit MMP and TIMP 
activity. 
5.2.11 Reactive oxygen species (ROS) analysis 
ROS in pulmonary fibroblasts was analyzed under aforementioned growth 
conditions using CellRox® deep red reagent, as per the manufacturer’s protocol. Briefly, 
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rat lung fibroblasts were seeded in well plates. They were allowed to attach and grow for 
24 hours in just the growth medium. Cells were incubated for 48 hours in CSE, TNF-α, 
CSE+PGG, or TNF-α+PGG before adding CellRox® Deep Red reagent at a final 
concentration of 5µM, followed by incubation at 37°C for 30 minutes. Cells were then 
washed thrice with PBS, and DAPI stain was added to visualize cell nuclei. Cells were 
washed again and were fixed with 4% formaldehyde before proceeding to imaging. 
5.2.12 Immunofluorescence imaging of elastin 
A different set of cells grown under the aforementioned conditions was imaged for 
elastin deposition. At 7, 14, and 21 days, cell layers were washed twice with PBS and fixed 
in 4% formaldehyde for 15 minutes at room temperature. This was followed by a very brief 
exposure (10-15s) to 5% beta mercaptoethanol (Calbiochem®, San Diego, CA) and 
Guanidine HCl (Avantor Performance Materials, Center Valley, PA) solution to digest the 
microfibrils surrounding the elastin fibers [278]. We observed that exposure for longer than 
60s digested the whole cell layer. Then cells were washed thrice with PBS and incubated 
with a 1% bovine serum albumin (BSA) (Seracare, Milford, MA) for blocking. FITC 
tagged anti-elastin antibody (Bioss Inc., Woburn, MA) was added to the cells at a 
concentration of 10µg/ml and incubated for 1 hour after which cells were washed thrice to 
remove any excess unbound antibody. DAPI (Thermo Fisher Scientific, Waltham, MA) 
was added to visualize cell nuclei, and after three washes, cells were mounted using 
aqueous mounting medium with anti-fading agents (Biomedia Corp., Foster city, CA). 
Images were captured using a EVOS XL Imaging system (Thermo Fisher Scientific, 
Waltham, MA) with the same exposure levels for all samples. 
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5.3 Results 
5.3.1 Pentagalloyl glucose (PGG) concentration characterization 
PGG did not damage the cells when grown for 14 days. Cells grown in 2, 5 and 10 
µg/ml concentrations of PGG did not show any significant reduction in cell viability as 
compared to their respective control group grown in DMSO (Figure 5-1). The FASTIN 
assay for elastin quantification showed that the 10 µg/ml concentration of PGG aided in 
achieving significantly higher matrix elastin (Figure 5-2).  
 
 
Figure 5-1: Live/Dead assay of rat pulmonary fibroblasts grown for 1 week 
in different concentrations of PGG dissolved in DMSO. Cells with 
equivalent amount of DMSO served as control in this study. Green 
represents live cells and red represents dead cells. Scale bar=400µm. 
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5.3.2 Cigarette smoke extract (CSE) characterization 
Live/Dead images of 1% and 5% CSE cell groups did not show any significant 
difference in cell viability. However, from 10% CSE onwards, cell death was evident as 
seen in both the Live/Dead and dsDNA quantification assays as shown in Figure 5-3. From 
this, we concluded that a final 5% solution of prepared stock CSE is apt for our cell culture 
studies.  
 
Figure 5-2: Bar graph showing quantified matrix 
elastin after three weeks, from the cell culture of rat 
pulmonary fibroblasts grown in different PGG 
concentrations (n=3). The values obtained were 
normalized to DMSO group values in order to 
compare (dashed line). * represents significantly 
different from DMSO group. 
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Figure 5-3: Viability of cells grown in various concentrations of CSE (A) Live/Dead 
assay of rat pulmonary fibroblasts grown for 96 hours in different concentrations of 
cigarette smoke extract (CSE). Green represents live cells and red represents dead cells. 
Scale bar=400µm (B) Bar graph showing the cell number quantified using Picogreen 
dsDNA fluorimetric assay (n=3).  * represents significantly different control group. 
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5.3.3 Relative expression of LOX, LOXL1 and ELN genes 
Quantitative PCR analysis of mRNA obtained from all the groups showed that 
expression of all three genes was upregulated in all of the groups as compared to the 
DMEM group at week 1. The TNF-α+PGG group showed the highest LOX expression 
with 6-fold upregulation as compared to the DMEM group, while the other groups stand at 
2-3 fold expression. The elastin gene was not upregulated in the TNF-α group, while the 
other groups showed a 4-6 fold increase. These expression levels returned to the same level 
as housekeeping gene expression by week 2. A comparison of expression levels at week 1 
and week 2 shows that the PGG treated groups had higher expression of these genes 
compared to their respective controls as shown in Figures 5-4. 
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Figure 5-4: Bar graphs showing relative expression of LOX and elastin genes, LOX (A-B), LOXL1 
(C-D) and ELN (E-F) genes in rat pulmonary fibroblasts treated with TNF-α, TNF-α+PGG, CSE 
and CSE+PGG. Dashed line represents control group value. # represents significantly different from 
control group. 
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5.3.4 Elastin quantification 
As compared to the DMEM group, by week 2, tropoelastin in the medium was 
found to be higher in the TNF-α and TNF-α +PGG groups, while the CSE and CSE+PGG 
groups showed a decrease in tropoelastin levels. However, by week 3 neither of the above 
mentioned four groups showed an increase in tropoelastin suggesting that the inflammatory 
conditions may be hampering tropoelastin production.  
On the other hand, the PGG and TNF-α +PGG groups showed significantly 
increased matrix elastin deposition in cell cultures by week 2 and week 3, whereas the 
others remain lower as compared to the DMEM group. The CSE group shows the least 
Figure 5-5: Bar charts showing elastin quantified in the spent medium (A-B) and cell culture 
matrix (C-D) of rat fibroblast cultures after weeks 2 and 3 treated with TNF-α, TNF-α+PGG, 
CSE and CSE+PGG. Dashed line represents control group value. # represents significantly 
different from control group. Other significant differences between specific groups are also 
shown separately. 
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matrix elastin deposited at both weeks 2 and 3 without any increase in the amount. On the 
other hand, the CSE+PGG group shows a tremendous increase in matrix elastin deposition 
by week 3 suggesting the effect of PGG in elastin deposition. These trends are depicted in 
the bar graphs in Figure 5-5. 
5.3.5 LOX activity 
As shown in Figure 5-7, LOX activity measured at week 1 showed that the PGG 
and TNF-α +PGG groups have higher activity than the DMEM group, while the CSE group 
showed lower LOX activity than the DMEM group. Again, with the presence of PGG in 
the CSE+PGG group, LOX activity was on par with the DMEM group. The TNF-α and 
TNF-α +PGG groups showed similar LOX activity as that of the DMEM group, but the 
CSE seems to be impeding LOX activity. The significant difference between the CSE and 
CSE+PGG groups by week 2 clearly shows the role of CSE on LOX inhibition (Figure 5-
6). 
Figure 5-6: Bar charts showing LOX activity quantified in rat pulmonary fibroblasts treated 
with TNF-α, TNF-α+PGG, CSE and CSE+PGG. Dashed line represents control group value. 
# represents significantly different from control group. Other significant differences between 
specific groups are also shown separately. 
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5.3.6 Gelatin zymography and Reverse zymography 
Gelatin zymography clearly allowed us to visualize MMP activity. The TNF-α and 
CSE groups showed substantial MMP activity, which was diminished in their respective 
PGG treated groups at weeks 1 and 2 (Figure 5-7). Densitometry analysis performed using 
GelQuant software allowed us to quantify the intensity of the bands. Medium samples from 
the CSE+PGG group had significantly lower band intensity compared to the CSE group at 
both weeks 1 and 2. On the other hand, the TNF-α+PGG group at week 1 had lower levels 
of MMP-9 activity (p=0.06), but at week 2, it was significantly lower than the TNF-α 
group.  
 
A separate part of the gel with the same samples, incubated in development buffer 
along with PGG (20µg/ml) showed reduction in MMP-9 (92kDa) bands (data not shown). 
Figure 5-7: Gelatin zymography images showing MMP 9 activity in cell culture medium treated with 
TNF-α and CSE, treated with PGG respectively (A and B). Densitometry quantification of MMP 
activity bands from gelatin zymography. Dashed line represents control group value. # represents 
significantly different from control group. Other significant differences between specific groups are 
also shown separately. 
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This shows that PGG can inhibit MMP activity in an extracellular environment. In reverse 
zymography, TIMP activity was analyzed, which showed that PGG treated cells have less 
TIMP activity (Figure 5-8). This might point towards the reduced requirement of TIMPs 
with PGG acting to inhibit MMP activity. These results show that PGG can effectively 
inhibit MMP activity, which could be of huge potential for preserving elastin from 
elastolysis.  
 
5.3.7 Immunofluorescence of elastin 
We could observe significant elastin deposition in cell cultures by week 3. 
Immunofluorescence imaging of elastin deposited in the cell cultures depicted fibrous 
elastin deposited in the PGG treated group compared to the control DMEM group. The 
PGG treated group showed fibrous elastin deposition in the cell layers while the control 
group showed small and localized elastin deposits near the cells. Immunofluorescence 
studies reinforced the aforementioned quantitative elastin results. This supported our 
elastin quantification results that we obtained from the cell culture layers (Figure 5-9). 
Figure 5-8: Reverse zymography images showing TIMP activity in cell culture medium 
treated with TNF-α and CSE, treated with PGG respectively. 
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5.3.8 ROS analysis 
We observed a significant reduction in the ROS found in rat pulmonary fibroblasts 
in the TNF-α+PGG and CSE+PGG groups compared to the TNF-α and CSE groups. This 
clearly confirmed that PGG could keep ROS levels lower and thereby asserting the anti-
oxidant property of PGG (Figure 5-10). 
Figure 5-9: Immunofluorescence imaging of cell cultures at 3 weeks to visualize 
elastin. Green represents elastin in the cell culture matrix. Blue represents cell nuclei. 
Scale bar=200µm 
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5.4 Discussion 
We have investigated the effects of PGG, a polyphenol and a derivative of tannic 
acid, on elastin deposition, MMP activity and ROS levels in an in vitro model using rat 
pulmonary fibroblasts. Fibroblasts are one of the key cells that make elastin and other extra-
cellular matrix proteins[40]. Pulmonary fibroblasts are important in the pathology of 
COPD as they participate in ECM remodeling. There are in vitro models that have used 
Figure 5-10: Visualization of reactive oxygen species (ROS) in rat pulmonary 
fibroblasts using CellRox Deep red reagent. Red and yellow represent ROS inside 
cells and blue represents DAPI staining of nuclei. 
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pulmonary fibroblasts to study the disease [279, 280]. Various agents have been used to 
mimic the inflammatory conditions that exist in COPD, but cigarette smoke extract has 
emerged as a key model [281]. TNF-α has a very important role as a pro-inflammatory 
cytokine in lung pathophysiology [282, 283]. The main advantage of using CSE is that it 
correlates well with in vivo exposure. Soluble components of cigarette smoke pass through 
the mucus layer before reaching the epithelial cells of alveoli that remain distal to the 
airways. We have used both CSE and TNF-α to mimic the disease in cell culture. CSE is 
prepared by bubbling the smoke directly from cigarettes into warm PBS or cell growth 
medium. Usually this solution is considered to be 100% stock and is added to cell cultures 
to obtain different final concentrations. We bubbled smoke from 2 cigarettes (Marlboro 
100s) in 10 ml of PBS. We have checked for cell viability of pulmonary fibroblasts grown 
in different conditions of CSE before deciding a 5% solution of the stock to be suitable for 
our experiments.  
We have three important findings that are discussed here. First, we observed that 
PGG can significantly increase elastin deposition in the cell layer matrix. We have 
observed that both TNF-α and CSE treatment caused an increase in elastin mRNA 
expression at week 1. This can be related to increased elastin expression in COPD patients 
[24, 284], as an attempt by the lungs to repair the damaged elastin. We then quantified the 
elastin protein in the medium to see if the protein is produced in the same fashion as that 
of gene expression. The CSE group has less medium elastin than the control group. Cells 
supplemented with PGG showed more medium elastin production compared to their 
respective controls (TNF-α+PGG> TNF-α, CSE+PGG>CSE). By the end of week 3, this 
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elastin was quantified to see if it was deposited in the matrix. In a similar fashion to medium 
elastin, the TNF-α and CSE groups did not show any significantly higher elastin deposition 
in the matrix compared to the DMEM group. We believe that the higher amount of elastin 
deposited in the TNF-α +PGG and CSE+PGG groups, with low medium elastin found in 
these groups, shows the effect of PGG in precipitating elastin into the matrix. This 
phenomenon can be compared to that observed by Jimenez et al., with 1 µg/ml tannic acid 
and ellagic acid in dermal fibroblast cultures [285]. They have also observed lesser elastin 
degradation when elastin was combined with tannic acid. Precipitation of elastin with PGG 
has been shown in our previous studies confirming that PGG binds to elastin and 
coacervates it [199]. In a separate set of experiments, we have observed that treatment of 
cells with CSE (5% final concentration) for one week followed by PGG (10µg/ml) 
treatment for one week as a therapy increases elastin deposition (n=3 per group; p-
value=0.1) compared to cells grown in DMEM after one week of growth in CSE (data not 
shown). Further proof of the action of PGG comes from our observation that LOX mRNA 
expression increased in cells treated with PGG, and its activity remained higher than 
respective non-PGG treated controls. CSE has been shown to inhibit cross-linking of 
tropoelastin molecules to form elastic fibers [286]. Li et al., point out in their review that 
LOX can be affected at many stages including mRNA expression [287]. However, we 
found an increase in LOX mRNA expression at week 1, which returned to the same 
expression level as housekeeping gene. We believe this may be because of the variety of 
cigarettes and the concentration of CSE we have chosen to add to the cell cultures. Gao et 
al., have shown that LOX mRNA transcription can be perturbed using cigarette smoke 
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condensate, but not extract, at a concentration of 80 µg/ml or more [288]. Elastin 
degradation is an important step in the pathophysiological path of COPD. Elastin 
degradation results in elastin derived peptides (EDPs), which have been shown to be 
chemoattractants for monocytes. Sellami et al., have even shown that intra-tracheal 
injection of VGVAPG amino acid (one of the EDP sequences) causes emphysema in a 
murine model [62]. We have shown here that treatment of pulmonary fibroblasts with PGG 
increases elastin mRNA expression and increases elastin deposition in the matrix even with 
lower medium elastin production by cells exposed to CSE and CSE+PGG.  
Our second observation is about MMP activity in medium collected from the cell 
cultures. We quantified enzyme activity using gelatin zymography. There was a decrease 
in MMP activity in the TNF-α +PGG and CSE+PGG groups compared to the TNF-α and 
CSE groups respectively. These results are in agreement with many other studies that 
reported decreased MMP activity after treatment with polyphenols [207, 289]. We 
observed decreased band intensity when incubated in a solution containing 20µg/ml PGG. 
This shows that PGG can inhibit MMP activity outside the cells as well. Another interesting 
result comes from reverse zymography. We believe that ours is the first study to show this 
result using PGG in pulmonary fibroblast cultures. Lindner et al., have shown a spike in 
MMP-9 expression (90 fold) in human pulmonary fibroblasts after 24 hours of exposure to 
10 ng/ml of TNF-α [290]. On the other hand Ning et al., have observed that cigarette smoke 
stimulates MMP-2 activity in human fibroblast cultures [291]. However, we have only 
observed MMP-9 activity using zymography but not MMP-2 using zymography. This may 
be because of insufficient enzyme present in the medium to be detected or low expression. 
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We do not know if PGG decreases MMP-9 expression in pulmonary fibroblasts accounting 
for the decreased MMP activity seen in the medium from PGG treated groups. Another 
interesting observation is decreased TIMP activity in the cultures which had PGG added to 
them. This TIMP activity is not affected by incubation of the gel in development buffer, 
which contains PGG. This observation is supported by findings of Seifart et al., where they 
show that ATRA treatment reduces TIMP activity [292]. We also observed reduced TIMP 
activity in rats treated using doxycycline nanoparticles for four weeks (data not shown). 
This might point towards normalcy being restored in terms of TIMP activity, with MMP 
activity being kept in check by PGG treatment. 
Our third observation pertains to the anti-oxidant property of PGG. Polyphenols are 
equipped with multifactorial properties that are beneficial in controlling inflammation. 
Oxidative stress is an important factor present in COPD, which is caused by cigarette 
smoking in patients [293]. The anti-oxidant properties of polyphenols have already been 
documented [198, 294]. We saw a clear eradication of the signal from the fluorescent ROS 
substrate in cells supplemented with PGG along with TNF-α or CSE treatment. It is also 
interesting to note that this oxidative stress could have caused increased elastin expression 
in CSE and TNF-α groups of our experiment, as observed by Deslee et al., [295]. We 
believe this anti-oxidant property of PGG might help in controlling oxidative stress in 
COPD and thereby controlling damage in lungs. Finally, we also tested for collagen in cell 
cultures to investigate if PGG increases collagen deposition in the matrix. Finlay et al., 
[296] showed that collagen remodeling is a consistent feature of emphysematous lungs as 
supported by Mosquero et al.[297]. Increased collagen is seen as a process of repair by the 
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lungs. We found that PGG treatment does not cause any extra collagen creation either in 
soluble or insoluble forms (data not shown here). 
5.5 Conclusion 
In this research aim, we have shown that PGG treatment shows increased elastin production 
and deposition in rat pulmonary fibroblast cell cultures. Elastin damage has been shown to 
drive lung damage in emphysema. Thus, stabilizing and regenerating elastin can be a way 
to arrest the progression of this disease. Oxidative stress and MMP mediated connective 
tissue damage contribute towards the complexity of this disease. We have shown that PGG 
can suppress ROS levels and MMP activity in pulmonary fibroblasts significantly. We have 
also observed that PGG can increase elastin expression in pulmonary fibroblasts and helps 
form elastic fibers in the matrix. This shows PGG can be used as a multifunctional drug in 
the treatment of emphysema. 
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6 SPECIFIC AIM 4: TO INVESTIGATE WHETHER PGG LOADED 
NANOPARTICLES CAN BE TARGETED TO EMPHYSEMATOUS LUNGS 
AND WHETHER THEY INCREASE ELASTIN MATRIX DEPOSITION, 
THUS BRINGING BACK THE ELASTIC RECOIL OF LUNGS  
6.1 Introduction 
 Emphysema is a condition present in patients with COPD. Its characteristic 
features are chronic inflammation, oxidative stress, elastin damage and progressive 
alveolar destruction [241]. Improvement in lung function does not occur even after 
smoking cessation [298]. Cigarette smoke insult triggers the inflammatory response in 
lungs and over a period of time recruitment of more inflammatory cells causes excessive 
release of pro-inflammatory mediators leading to a disruption of protease-antiprotease 
balance in the lungs. Cigarette smoke also disrupts cell proliferative mechanisms, causes 
apoptosis, and inhibits alveolar and elastin repair, which make the condition irreversible 
[65, 68, 80].  
Elastin protein is very important to organs like the lungs as it provides elastic recoil 
for the ease of breathing. Elastin degradation has a significant impact on patients’ lung 
function, and it has received little attention as a potential target for treatment of 
emphysema. Loss of lung elasticity has been correlated to a loss of lung function in 
emphysema patients [61]. The inability of adults to regenerate elastin has been attributed 
to the lack of coordinated expression of all the molecules required in the process of 
synthesizing crosslinked elastin [46]. Moreover, EDPs act as chemo-attractants for 
monocytes and further increase the inflammatory burden on lungs [299]. 
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Preservation of elastin from damaging elastolytic activity is an important step 
towards preventing emphysema progression. If the lost elastin in the lungs is restored, then 
it is possible to reverse the disease. Pentagalloyl glucose (PGG) is a polyphenol that has 
been shown to preserve elastin from elastolysis in vascular tissues. It has also been shown 
to regenerate elastin in abdominal aortic aneurysm animal models [218]. Thus, in this 
research aim we tried to use PGG as a possible therapy for reversing mild emphysema in 
mice. We investigated if nanoparticles can be delivered through inhalation and the 
extension of their retention in lungs. Furthermore, we also study if PGG loaded BSA 
nanoparticle delivery to lungs can preserve elastin from degradation. 
6.2 Materials and methods 
6.2.1 Ex vivo PGG treatment 
Frozen rat lung and aorta pieces were cut, washed and lyophilized to record initial 
dry weights. One group of samples were incubated in 0.05% PGG in MES buffer 24 hours. 
The others were only treated in MES buffer for 15 minutes. Following this both control 
and PGG fixed samples were subjected to elastase challenge in 5U/ml porcine pancreatic 
elastase solution (supplemented with 100mM Tris, 1mM calcium chloride and 0.02% 
sodium azide; pH 7.8) for 24 hours. They were again lyophilized to measure final dry 
weight. Percentage weight loss was calculated in both groups (n=5 per group). A separate 
set of samples treated in the same way, without lyophilizing, were used for histological 
examination. 
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6.2.2 Elastase inhibition by PGG 
In order to investigate PGG’s ability to inhibit elastase activity, enzymatic assay 
was performed using N-Succinyl-Ala-Ala-Ala-p-nitroanilide (SucAla3-pNA) (Sigma-
Aldrich, St. Louis, MO) as substrate. Originally described by Beith et al., [300] in this 
assay, elastase cleaves this substrate into N-Succinyl-Ala-Ala-Ala and p-nitroanilide. 
Porcine pancreatic elastase (2U) was added to 120-µl of the substrate (2mg/ml) with or 
without PGG. Absorbance was measured at 410nm and percentage inhibition was 
calculated as the difference compared to absorbance of uninhibited sample. 
 
6.2.3 Preparation of DiR dye loaded BSA nanoparticles (DiR-BSA NPs) 
DiR dye (PromoCell GmbH, Heidelberg, Germany) loaded BSA (Seracare, Milford, MA) 
nanoparticles were prepared using desolvation method and conjugated to anti-elastin 
antibody (US Biological, MA, USA) for targeting purposes described previously [217-
220]. Briefly, 250 mg of BSA was dissolved in 4ml of DI water.  2.5 mg of DiR dye 
dissolved in acetone was added to BSA solution. The mixture was stirred for one hour at 
room temperature following the addition of glutaraldehyde (EM grade 70%, EMS, PA, 
USA) at a concentration of 42µg/mg BSA. The mixture was added dropwise to 24mlof 
ethanol while sonicating (Omni Ruptor 400 Ultrasonic Homogenizer, Omni International 
Inc, Kennesaw, GA). The mixture was sonicated on ice for 30 minutes. The DiR-BSA NPs 
were separated by centrifugation at 10,000 RPM for 10 minutes and washed with water by 
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resuspension. These nanoparticles were prepared fresh and conjugated the day before 
treatment to animals.  
6.2.4 Tagging NPs with elastin antibody 
DiR-BSA NPs were PEGylated (mPEG-NHS, PEG succinimidyl ester, MW 2000) 
(Nanocs, New York, NY) by incubating 2.5 mg of PEG with 10 mg of nanoparticles at 
room temperature for one hour. The elastin antibody (United States Biological, 
Swampscott, MA) was thiolated using Traut’s reagent. 1 mg/ml of Traut’s reagent prepared 
in HEPES buffer at pH 8.8. 10µg of elastin antibody was added to 34 µl of 1mg/ml Traut’s 
reagent and 400μl of HEPES buffer. The thiolation process was carried out at room 
temperature for 1 hour, followed by filtration through 30kDa MWCO filter at a 
centrifugation speed of 10000g for 1 min. Finally, the thiolated antibody and PEGylated 
NPs were combined and incubated on a rocker shaker overnight at 4°C, to obtain ELN-
DiR-BSA NPs. 
6.2.5 In vivo targeting of nanoparticles to mice lungs 
Eight-week-old male C57BL/c mice were subjected to intra-tracheal instillation of 
porcine pancreatic elastase and allowed to develop lung damage over 4 weeks of time. 
There were three groups of mice- viz. saline, one PPE injection at the starting (PPE1), and 
two biweekly injections (PPE2) at the start of weeks 1 and 3 (n=4 per group). After 4 
weeks, ELN-DiR-BSA NPs were injected at a dose of 10 mg/kg via tail vein. Twenty-four 
hours after injection, mice were euthanized to image lungs and other organs for DiR signal. 
After compliance measurement lungs, liver, aorta, kidneys and spleen were harvested to 
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check for DiR signal by imaging each organ with IVIS® Lumina XR Imaging system 
(Caliper Life Sciences, Waltham, MA) set to excitation/emission of 745nm/790nm. 
Background signal was subtracted before analyzing the signal intensities from the organs.  
6.2.6 Nanoparticle delivery via inhalation 
Six week old male C57BL/c mice (n=12) were used for this study. In an effort to 
cause uniform lung damage by elastase in both the lungs, animals were made to inhale 
elastase delivered by a nebulizer. Control animals received saline inhalations, while the 
elastase groups’ animals received one-time elastase inhalation of 13.67U/ml porcine 
pancreatic elastase solution (PPE) (Elastin Products Co., Owensville, MO), dissolved in 
phosphate buffered saline (PBS) and aerosolized using a nebulizer system (Braintree 
scientific, Braintree, MA). Mice were anesthetized using 2% isofluorane and placed in a 
12-pie cage for inhalations (Figure 6-1). The amount of aerosolized liquid deposited over 
15 minutes duration was determined before the experiment to optimize elastase and 
nanoparticle concentrations. Four weeks after elastase inhalation, when sufficient elastin 
degradation is demonstrated, ELN-DiR-BSA NPs were given either by inhalation (ELN-
DiR-Inh) route (n=3) (1mg/ml solution nebulized for 15 minutes) or via tail vein injection 
(ELN-DiR-IV) (n=3) (10mg/kg). Three days after administering nanoparticles, mice were 
euthanized and lungs were imaged as described before. In another study, one dose of either 
ELN-DiR-BSA NPs (ELN-DiR-6wk) or DiR-BSA NPs (DiR-6wk) (n=3 per group) were 
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delivered via inhalation after 3 days of damage and the animals were euthanized after 6 
weeks to observe retention of both particles in lungs (Figure 6-2). 
 
 
Figure 6-1: Nebulizer and pie cage set up for inhalation delivery of solutions. 
Figure 6-2: Timeline graph of animal study to deliver DiR-BSA NPs via inhalation and intravenous 
injections in mice. 
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6.2.7 Preparation of PGG loaded BSA NPs 
PGG-loaded BSA nanoparticles were prepared as described by Nosoudi et al., 
[204]. Briefly, 250 mg of BSA was dissolved (Seracare, MA) in 4 ml of deionized water. 
Pentagalloyl glucose (PGG, 125 mg) was dissolved in 200µl of dimethyl sulfoxide and 
added slowly to the BSA solution. After an hour of stirring, the mixture was added 
dropwise to 24 ml of ethanol under continuous sonication on ice for half an hour. 
Glutaraldehyde was added during stirring at a concentration of 12μg/mg protein (BSA). 
The elastin antibody conjugation procedure was similar to that of DiR-BSA NPs. 
6.2.8 Targeted delivery of PGG-BSA NPs in vivo 
Six week old male C57BL/c mice were divided into four groups i.e., healthy (n=6), 
non-treated (n=14), ELN-PGG-NP (n=6) and PGG-NP (n=6). As described above, healthy 
animals received saline inhalations while the other groups’ animals received one-time 
elastase inhalation of 25U/ml porcine pancreatic elastase solution (PPE) (Elastin Products 
Co., Owensville, MO), dissolved in PBS and aerosolized using a nebulizer system 
(Braintree scientific, Braintree, MA). 
After inhalation, mice were kept for 5 weeks to allow lung damage. One week post 
elastase challenge, ELN-PGG-NP group received two biweekly inhalations of ELN-PGG-
BSA NPs while PGG-NP group animals received similar biweekly inhalations of PGG-
BSA NPs (without elastin antibody conjugation). 1mg/ml solution of freshly prepared 
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particles was nebulized for 15 minutes using the same equipment described above (Figure 
6-3).   
 
6.2.9 Measurement of air volume and mean lung volume intensity 
Mice were anesthetized and micro CT scans were performed on their lungs at 1 and 
5 weeks post elastase challenge, using Skyscan 1176 micro CT (Bruker, Belgium). List 
mode scan with 12 frames was performed using the following parameters: voltage-50 kV, 
filter-Al 0.5 mm, current-500 µA, resolution-35 microns, exposure-50 ms with a rotation 
step of 0.7°. Images were reconstructed and analyzed using manufacturer provided 
software. After reconstructing the datasets, they were analyzed using CTAn software. 
Lungs were segmented out from other tissues and blood vessels using specific set of 
operations. 3D analysis of these datasets yielded the volume of air in the lungs at different 
phases of breathing. Absorption coefficient was calibrated with a water phantom to get 
accurate Hounsfield units value for the intensity of the segmented lungs. Using the 
Figure 6-3: Timeline graph of animal study to deliver PGG-BSA NPs in mice. 
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segmented out lungs as mask, mean intensity of the lung tissue was calculated from an 
intensity histogram (Figure 6-4). 
  
6.2.10 Measurement of lung functional parameters 
At the end of the study, mice were anesthetized using xylazene and ketamine to 
perform tracheotomy. Dosages for xylazine and ketamine were 5mg/kg (diluted 1:10) and 
80mg/kg respectively. The animal was allowed to go into deep anesthesia so as to reduce 
the breathing rate. It was important to keep the animal in this state to avoid the animal fight 
the ventilator. An incision was made on throat and fascia was separated using forceps to 
Figure 6-4: Lung segmentation and mean lung volume 
intensity measurement using CT-An software. 
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visualize trachea. Trachea was nicked and a connector tube was inserted into it. After 
tightly connecting the tube to trachea by a double knot suture, the animal was connected to 
FinePointe resistance and compliance system (DSI, St. Paul, MN) for measurements. The 
instrument had a ventilator that pumped known amounts of air and simultaneously 
measured an array of parameters such as lung dynamic compliance, resistance and tidal 
volume. The animals were euthanized by exsanguination under 4% isofluorane. Following 
the opening of chest cavity, whole body flush was performed by injecting heparinized 
saline in the right ventricle and cutting open the right atrium. This allowed both pulmonary 
and systemic circulatory vessels to be flushed. After the organs were perfused, one half of 
the lungs was frozen using liquid nitrogen for protein analysis while the other half was 
fixed in neutral buffered formalin. Other organs such as liver, spleen, kidneys were 
collected and fixed in neutral buffered formalin. 
6.2.11 Measurement of MMP activity 
Frozen lung pieces were homogenized in RIPA buffer (10 mM Tris-Cl, 1 mM 
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM 
PMSF; pH 8.0). After disrupting the tissue with a hand held homogenizer for 5 minutes, 
the samples were sonicated on ice for five more minutes to ensure complete 
homogenization. They were then spun at 10,000 rpm for 5 minutes and the supernatant was 
collected. MMP activity in the tissue homogenate samples was measured using internally 
quenched peptide substrates for MMPs 2&9 (Ex/Em= 280/360 nm, MMP Substrate III, 
Anaspec, CA) and MMP 12 (Ex/Em = 325/393 nm, 390 MMP FRET Substrate V, Anaspec, 
CA). One mg of the substrate was dissolved in 50 µl of DMSO, and the solution was diluted 
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in 10 ml of development buffer (50 mM Tris Base, 5 mM CaCl22H2O, 200 mM NaCl, 
0.02% brij 35). 2µl of the substrate stock solution and 2 µl of the extracted protein were 
mixed with 96µl of the development buffer and incubated for one hour at 37°C. A 
fluorescent plate reader was used to read endpoint florescence intensity. 
6.2.12 Histology 
Sections from formalin fixed lung pieces were assessed for damage in lungs. 
Processed tissue samples were embedded in paraffin and sections of 5μm thick were made 
from the sagittal face. H&E staining was used to observe general structural characteristics 
and enlargement of alveoli. VVG staining (Polysciences Inc., Warrinton, PA) was 
performed according to manufacturer’s protocol to study elastin damage in the alveolar 
walls of the tissue. 
6.3 Results 
6.3.1 Ex vivo PGG treatment 
Weight loss after elastase challenge was determined in both aorta and lung samples 
to investigate if PGG can protect elastin from damage. PGG fixed samples showed 
significantly less weight loss after elastase challenge (Figure 6-5). This finding was also 
confirmed using Verhoff van Gieson staining of sections. Elastin was preserved in both 
lungs and aorta samples in PGG treated samples while it was degraded in the untreated 
samples after elastase challenge (Figure 6-5). FASTIN assay was performed on lung 
samples to quantify the amount of elastin per mg of dry tissue to further confirm the 
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stabilization of elastin. Concurring with the previous results, PGG fixed samples showed 
strikingly more elastin than control samples (Figure 6-6). 
Figure 6-5: Results showing protection of elastin by PGG from elastase challenge ex 
vivo. A and B show percentage of weight loss in control and PGG fixed lung and aorta 
samples. C and D show representative histological sections of PGG fixed lungs and 
aorta where elastin is preserved. E and F show representative histological sections of 
control lung and aorta samples where elastin is depleted due to elastase challenge. 
Inset picture shows elastin preserved in PGG treated group versus elastin damaged in 
control group * shows significant difference from control group. Elastin in lungs is 
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6.3.2 Elastase inhibition by PGG 
PGG inhibited elastase activity in a concentration dependent manner just after 20 
minutes of treatment. Starting from 1µg/ml PGG concentration, elastase activity was 
inhibited by 40% compared to control samples. With a maximum concentration of 20µg/ml 
PGG inhibited up to 60% of PPE activity. This result suggests that PGG might also 
decrease elastase activity and therefore improves elastin stabilization further (Figure 6-7).  
   
Figure 6-6: Bar chart showing elastin quantified in 
control and PGG fixed lung samples following 
elastase challenge. PGG fixed samples showed 
significantly higher elastin per mg dry tissue. * shows 
significant difference from control group. 
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6.3.3 In vivo targeting of nanoparticles to mice lungs 
IVIS imaging of mice lungs showed scintillating difference in the amount of 
fluorescence seen among the groups. Saline injected mice did not show any fluorescence 
signal while elastase damaged mice lungs showed significantly high amounts of 
fluorescence. Aortae from same animals, that were healthy did not show any signal, further 
confirming that nanoparticles only target degraded elastin (Figure 6-8). We noticed a 
decrease in the signal in the lungs of mice, which were given two doses of PPE. This might 
be because of excess elastin loss, which impacts the binding of nanoparticles. A plot of 
DiR signal versus elastin quantified from the mice lungs shows a negative correlation 
Figure 6-7: Line graph showing inhibition of elastase activity by various 
concentration of PGG. * shows significant difference from control group 
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between these variables suggesting elastin damage is directly correlated for the 
nanoparticle signal (Figure 6-9). 
 
 
 
 
 
Figure 6-8: Fluoroscence from DiR NPs show successful targeting of anti-elastin antibody 
tagged nanoparticles to only lungs with elastin damage. Comparison of signal from aorta 
proves that these nanoparticles spare the healthy elastin in them. 
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6.3.4 Histology 
Hematoxylin and Eosin staining of control, PPE1 and PPE2 mice lung samples 
showed the extent of damage correlated with elastase treatment. The damage increased 
with the increase in the elastase dose. Verhoff van Gieson staining for elastin also indicated 
less elastin around the alveolar walls of PPE damaged mice lungs. Immunohistochemistry 
with elastin antibody (US Biological, Salem, MA) showed depleted elastin in the same 
areas giving us a model validation and targeting of our nanoparticles to damaged elastin 
(Figure 6-10). 
6.3.5 Nanoparticle delivery via inhalation 
With an aim of creating uniform but also a milder damage to lungs, mice were 
allowed to inhale elastase instead of intra-tracheal instillation. We compared dose delivered 
Figure 6-9: Plot of elastin quantified in control, PPE1 and PPE2 group mice lungs 
versus DiR fluorescent signal found in them. Pearson’s correlation coefficient 
between DiR signal and elastin is -0.79. This means increasing signal corresponds to 
reduced elastin in the lungs. 
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by either inhalation or systemic route (Figure 6-11A). We observed less signal counts in 
the inhaled nanoparticle group compared to tail vein injected group clearly suggesting that 
systemic delivery was more effective in targeting lungs. Although the concentration of 
particles given via nebulizer was matched with that of tail vein injection dosage, the whole 
body inhalation setting might have affected the amount of particles inhaled and therefore 
caused less signal in inhalation group. Next, we investigated if elastin antibody conjugated 
nanoparticles stay in the lungs for a longer time compared to unconjugated inhaled 
particles; animals were allowed to survive for 6 weeks after administering nanoparticles. 
We observed that even after 6 weeks, elastin conjugated particles persisted in the lungs 
with just one inhalation (Figure 6-11B).  
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Figure 6-10: Histological analysis of lung sections from control, PPE1 and PPE2 groups (left to right) 
of mice. A-C show Hematoxylin and Eosin staining depicting lung tissue damage (Scale bar=50µm). 
D-F show Verhoff van Gieson (VVG) staining depicting loss of elastin from the alveolar septae (Scale 
bar=20µm). G-I show immunohistochemistry which again depicts loss of elastin along the alveolar 
walls. (Scale bar=50µm). 
116 
 
 
Figure 6-11: Fluorescence images of lungs showing nanoparticle 
targeting via different routes (A) Fluoroscence from ELN-DiR-BSA 
NPs show successful targeting of anti-elastin antibody tagged 
nanoparticles to only lungs with elastin damage via both intravenous 
and inhalation routes of delivery. (B) Nanoparticles conjugated with 
elastin antibody (ELN-DiR-BSA NPs) are found in mice lungs after 
6 weeks of inhalation while unconjugated nanoparticles (DiR-BSA 
NPs) are cleared. 
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6.3.6 Measurement of air volume and mean lung volume intensity 
Average volume of air in the lungs was measured at weeks 1 and 5 for all mice. We 
did not notice any significant change in this volume between 1 and 5 weeks (all the groups 
showed about 250 mm3 of air in their lungs) (Figure 6-12A). The mean lung volume 
intensity, which quantifies the damage of tissue, has also remained same in all the groups 
without any statistically significant difference (Figure 6-12B). This data clearly suggests 
that only milder emphysema was induced with the elastase treatment, which was enough 
to test the loss of elastin without changing the lung functional parameters drastically. 
 
Figure 6-12: Bar charts showing lung volume parameters measured using micro CT (A) Bar 
chart showing average volume of air in the lungs of all mice groups in the study, measured at 
weeks 1 and 5 post elastase challenge. (B) Bar chart showing mean lung volume intensity 
values (HU units) of all mice groups in the study, measured at weeks 1 and 5 post elastase 
challenge. 
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6.3.7 Measurement of lung functional parameters 
The most important finding of this study came from observing the compliance and 
resistance of the lungs after elastase inhalation. We noticed a small dynamic compliance 
increase in elastase treated mice (n=12) compared to the healthy subjects (n=6) (0.03 vs 
0.024 ml/cm H2O; p<0.05). When, PGG loaded nanoparticles were delivered after elastase 
treatment, we found that compliance was restored in ELN-PGG-NPs group of mice (n=6) 
(0.025 ml/cm H2O) but not PGG-NPs (n=5) (0.03 ml/cm H2O) (Figure 6-13). Similarly, 
lung resistance was lower elastase treated mice compared to control healthy mice (1.75 vs 
1.108 cm H2O/ml/s). Lung resistance in ELN-PGG-NPs group was intermediary to control 
healthy mice and elastase-treated groups (1.35 cm H2O/ml/s). PGG-NPs group had similar 
reduced lung resistance value (0.91 cm H2O/ml/s) as that of elastase-treated group (Figure 
6-14). Falling on the same lines, tidal volume of healthy mice was the smallest, increased 
Figure 6-13: Bar chart showing dynamic lung compliance 
(Cdyn) values in all groups of mice. Differences between 
groups are shown specifically using lines. 
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in elastase-treated group (138.5 vs 160.6 mm3; p<0.05). ELN-PGG-NPs group showed a 
trend of improvement (145.9 mm3) of tidal volume, while PGG-NPs group showed no sign 
of decrease in tidal volume (160.8 mm3). These results indicate that only a mild 
emphysema was induced in mice lungs but with a damage to elastin (Figure 6-15) and PGG 
loaded and elastin antibody targeted nanoparticles did improve lung parameters 
 
Figure 6-14: Bar chart showing lung resistance values 
in all groups of mice. 
Figure 6-15: Bar chart showing tidal volume 
values in all groups of mice. Differences between 
groups are shown specifically using lines. 
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6.3.8 Measurement of MMP activity 
MMP 2, 9 and 12 activities were measured using specific FRET substrates. The 
group of mice, which were left untreated, had the highest amount of MMP activity per mg 
protein in their lungs. This activity came down in the groups treated with ELN-PGG-NPs 
and PGG-NPs. Control group of mice that were not treated with elastase (healthy) had the 
lowest MMP values and PGG groups also reduced MMP levels to almost similar levels 
(Figure 6-16). This shows that PGG nanoparticles can inhibit MMP activity in vivo. 
 
Figure 6-16: Bar charts showing MMP 2&9 and 12 activities quantified 
in lung samples. Significant differences between groups are shown using 
lines. 
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6.3.9 Histology 
Verhoff van Gieson staining for elastin indicated less elastin around the alveolar 
walls of non-treated group mice lungs (Figure 6-17 A-D). Control mice had intact elastin 
around the alveoli. ELN-PGG-NP group had elastin preserved along the alveoli compared 
to the diminished elastin in non-treated group. Immunohistochemistry with elastin 
antibody showed similar observation of depleted elastin in non-treatment group (Figure 6-
17 E-H). In ELN-PGG-NP group, more elastin was present in the alveoli with preserved 
air spaces. PGG-NP group had intermediary elastin preservation as compared to ELN-
PGG-NP group. Luna stain showed elastin fibers depleted from the alveolar walls of non-
treated lungs, while ELN-PGG-NP group showed retention of elastic fibers (Figure 6-17 I-
L).  
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Figure 6-17: Histological examination of mice lungs. A-D show Verhoff van Gieson (VVG) staining 
of control, non-treated, ELN-PGG-NPs and PGG-NPs group lungs. Loss of elastin fibers from the 
alveoli can be noticed in the non-treated group compared to control and ELN-PGG-NP group. E-H 
show immunohistochemistry of the above groups with anti-elastin antibody. Results depict elastin 
preserved in ELN-PGG-NP group lungs while it can be seen eroded in the non-treated group and 
PGG-NP group. Final row shows luna staining of mice lung sections (I-L) which also shows 
preservation of elastin fibers along the alveolar walls (purple fibers) with ELN-PGG-BSA NPs 
treatment.  
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6.4 Discussion 
Here we show that PGG loaded nanoparticles can be targeted to degraded elastin in 
the emphysematous lungs and do they prevent further loss of elastin in lungs and improve 
lung properties.  Elastase model of emphysema was used to achieve elastin damage that 
led to changes in lung functional parameters. Elastase emphysema facilitates faster 
induction of disease as compared to smoke inhalation [301]. Although hamsters are the 
most susceptible to lung damage owing to their low alpha-1 antitrypsin levels [302], rats 
and mice offer a more convenient option to study this damage using elastase model. 
Between rats and mice, rat lungs are less susceptible to elastase injury [303]. Additionally, 
mice offer possibility of manipulation of genes (knockout and knock-in) so that the 
molecular mechanisms of disease progression and therapy can be studied. Therefore, we 
used a mouse model of emphysema for this research.  
First we investigated if PGG can protect elastin in the lungs from elastase challenge. 
We could demonstrate elastin preservation in both lung and aorta tissues treated with PGG 
followed by elastase challenge ex vivo. Tam et al., have shown similar result on 
preservation of native elastin in porcine aortic valve leaflets treated with a novel fixative 
containing PGG as one of its components [304]. Isenburg et al., have previously shown 
that periadventitial application of PGG on aorta hindered the development of abdominal 
aortic aneurysm in rats [276]. Nosoudi et al., have not only observed elastin preservation 
but also reported elastin regeneration after delivery of PGG loaded nanoparticles in a rat 
model of abdominal aortic aneurysm [305]. We observed significantly lower loss of weight 
after elastase treatment in PGG treated lungs. PGG is shown to bind to elastin and inhibit 
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elastase mediated degradation of elastin.  Our observation of PGG also inhibiting PPE 
activity in vitro suggests that PGG might act dually, first by binding to elastin in lungs and 
protecting it from degradation, while free PGG also can bind to the PPE enzyme and make 
it less active. 
Next, we demonstrated the reproducibility of our targeted nanoparticle delivery in 
mice by using elastase intra-tracheal instillations. Similar to our previous results with rats, 
we observed no fluorescence signal from lungs of control mice (saline instillation), whereas 
elastase challenged mice lungs showed significant signal corresponding to ELN-DiR-BSA 
NPs. Aortae, where healthy elastin was present, did not show any signal, thereby 
confirming that elastin antibody bound nanoparticles only target degraded elastin. We 
further show that ELN-DiR-BSA NPs remain in lungs 6 weeks after one-time nanoparticle 
inhalation. Thus, such nanoparticles can be used for prolonged drug delivery to the lungs. 
Our elastase inhalation only caused mild emphysema in mice. There are several 
million patients are in the mild phase of emphysema and currently have no treatments to 
further prevent disease progression. According to a result published by Goossens et 
al.,[306] 47% of COPD patients are in mild stage of emphysema. According to a survey 
conducted by the National Health and Nutrition Examination Survey (NHANES) during 
2007-2010, 20.1% of the US population was estimated to have COPD, with 10.9% and 
7.8% were present in the mild and moderate stages of emphysema respectively [307]. 
According to a report published in 2011 by Fitch et al., number of patients with mild 
emphysema was 30% while 53% were grouped into moderate emphysema stage [308].This 
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shows that an increasing attention is required to stop the progression of disease to reduce 
the economic burden. Our studies with elastase inhalation allowed us to create elastin 
damage without decline in the lung function drastically so as to obliterate the tissue beyond 
repair. There are not many consistencies in the literature for extent of lung damage with 
elastase instillation. For example, Hamakawa et al., used 0.25 IU of PPE via intra-tracheal 
instillation and observed a change in compliance between control and PPE treated mice at 
21 days (~0.02 vs 0.05ml/cm H2O) [105]. On the other hand, Szabari et al., used 6 IU of 
PPE, which is 24 times more than Hamakawa et al study and have observed similar damage 
after 21 days [111]. Takano et al.  used 0.25 IU, 1 IU and 2 IU of PPE and have not observed 
any significant deviation in compliance from the control group of animals [309]. Cruz et 
al. have observed a decrease in the amount of elastic fibers in non-reated mice lungs 
compared to healthy controls (9.5 % vs 10.4%) [171]. Barrutia et al. have also used 6U of 
PPE to achieve significant damage to the lung parenchyma [310]. Following a more 
incisive approach, Vidal et al., have intubated mice for injecting 2U/100g body weight to 
observe very high damage to the lungs. In this context, our effort to induce a more 
uniformly distributed lung damage with a whole body inhalation of elastase has resulted 
only in change in lung compliance. Lung compliance is a parameter that depends on the 
elasticity of the tissue. Loss of elastin because of elastase activity has caused a slight but 
significant increase in the lung compliance in elastase-treated group (n=12) compared to 
healthy control group. When treated with ELN-PGG-BSA NPs after elastase treatment, 
lung compliance reduced to the same as that of control healthy group animals. These results 
clearly suggest NPs delivered PGG and inhibited elastase mediated damage to the lungs.  
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When treated with nanoparticles without elastin antibody conjugation (PGG-BSA NPs), 
we did not see change in lung compliance clearly suggesting that nanoparticles were 
cleared without an active targeting mechanism and were unable to retain and deliver PGG 
to the lungs. Elastin was preserved in ELN-PGG-NP group as seen in histological sections. 
Luna stain clearly demarcates elastin loss in non-treated and PGG-NP groups as opposed 
to ELN-PGG-NP group.  
We have also observed a significant reduction in the MMP activity with our PGG 
nanoparticle therapy. This result is significant as MMPs have been known to drive the 
disease forward by degrading extracellular matrix components. A green tea polyphenol (-
)-epigallocatechin 3-gallate has been shown to inhibit MMP2 secretion in glioblastoma 
cells [311]. With respect to emphysema, polyphenols like curcumin and xanthohumol have 
also been investigated for matrix metalloproteinase activity inhibition and even anti-
inflammatory effects [209, 210]. Coupled with elastin preservation property of PGG, 
inhibition of elastase and MMP activity could be very beneficial in keeping lung damage 
in emphysema. 
6.5 Conclusion 
In conclusion, this research demonstrates the proof of concept for targeted delivery of 
nanoparticles in mice. We show that elastin antibody conjugation allowed the nanoparticles 
to remain in the lungs. PGG was shown to effectively preserve elastin in lung ex vivo, by 
binding to elastin as well as inhibiting elastase activity. A mild emphysema was created by 
elastase inhalations to achieve elastin damage in lungs in mice. Delivery of PGG NPs to 
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mild emphysema mice model protected elastin from degradation and retained lung 
compliance the same as control healthy animals. This suggests PGG, when delivered 
locally by targeted nanoparticles, has the potential to stabilize and regenerate elastin. 
Coupled with its anti-oxidant and elastase inhibition properties it can halt the progression 
of mild emphysema. 
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7 CONCLUSIONS AND RECOMMENDATIONS  
7.1 Conclusions 
Elastin is an essential protein for maintaining elasticity of lungs and cells cannot 
repair elastin that is degraded due to inflammation in lungs in emphysema. Elastin 
degradation products are also capable of driving the inflammatory cycle by acting as 
chemokines for attracting inflammatory cells from blood stream. Treatments have so far 
focused on stopping inflammation by anti-inflammatory drugs, but such drugs cannot 
repair lost elastin in lungs. This permanent loss of elastin seriously affects the normal 
functioning of lung, even with subsided inflammation. Therefore, protecting elastin from 
degeneration and helping cells deposit mature elastin in the lungs can help in bringing back 
the elastic recoil and reverse the disease. With this aim in mind, we have developed unique 
albumin based nanoparticles that can target damaged elastin in the lungs. We showed that 
the anti-elastin antibody conjugation to these nanoparticles makes them stick damaged 
elastin in lungs for up to 6 weeks. After successfully demonstrating this targeting, we 
delivered doxycycline-loaded particles to the lungs. We showed that one dose of our 
nanoparticles loaded with doxycycline inhibited the MMP activity for 4 weeks. We further 
show that PGG can preserve elastin and inhibit elastase activity in an ex vivo setting. 
Further research was carried out to test if PGG delivered with NPs can target 
emphysematous lungs and protect it from progression of the disease. Animals treated with 
PGG nanoparticle showed more elastin in the lungs than the non-treated controls. MMP 2, 
9 and 12 activities were suppressed when treated with PGG nanoparticle therapy and lung 
compliance remained same as that of control healthy animals. With these initial promising 
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results, we hope to take PGG treatment forward to develop it as a reliable therapeutic for 
emphysema treatment at an early stage of the disease. 
7.2 Recommendation for future work 
I. Our in vitro and in vivo data from this research shows that PGG can reduce 
MMP activity. It would be interesting to investigate the mechanism of this 
to gain further insight on the role of PGG. It will be useful to observe if this 
inhibition is due to impeded production of MMPs at cellular level or an 
extracellular inhibition of their activity. This can be done by following the 
same procedure as described in this dissertation, by culturing rat pulmonary 
fibroblasts and evaluating expression levels of MMPs with and without 
PGG treatment.  
II. In this dissertation, we show the beneficial properties of PGG such as anti-
oxidant property, MMP inhibition, and elastin deposition in rat pulmonary 
fibroblasts, under two types of inflammatory conditions to mimic 
emphysema. This approach can be extended to other types of cells like 
epithelial-fibroblast co-cultures, macrophage-fibroblast co-cultures and 
even human COPD subject pulmonary fibroblasts. This will provide us with 
more information as to how epithelial and macrophages, when subjected to 
inflammatory insult, interact with fibroblasts by producing various types of 
cytokines and whether PGG treatment can ameliorate these changes in vitro. 
III.  In this dissertation, we used the elastase model of emphysema. We have 
experimented with various dosages and routes of delivery of elastase to 
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induce damage. By inhaling elastase, we have observed a uniform damage 
of lung but this only created a mild damage. While PGG is able to protect 
the lung tissue with this amount of damage, it needs to be tested under 
conditions that are more aggressive. It would be useful to also test this in 
other animal models like cigarette smoke exposure, which produces more 
clinically relevant pathological changes compared to human emphysema. 
More information can be obtained by analyzing expression levels of 
inflammatory cytokines in the lung and remodeling extracellular matrix 
proteins.  
IV. It would be interesting to examine the role of alveolar macrophages in an 
animal model of emphysema. Alveolar macrophages are key players in the 
progression of this disease and whether PGG can influence their role is 
important in determining its mode of action. 
V. Pulmonary function tests are now used to diagnose COPD in patients 
currently. Looking at the importance of elastin in this disease, it would be 
very useful to develop a diagnostic tool using computed tomography (CT) 
and gold nanoparticle approach. With this novel elastin targeting in 
emphysematous lungs, gold nanoparticles can be targeted to damaged 
elastin in lungs. A quantitative relationship may be established to correlate 
the amount of nanoparticle binding and elastin damage in the lungs, giving 
us a way to detect elastin degradation and predict emphysema before it 
reaches to a moderate stage, where it becomes difficult to treat. 
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VI. We have shown that PGG assists in deposition of elastin in the matrix by rat 
pulmonary fibroblasts in vitro. As cited in the literature, previous work in 
our lab has also shown that it binds to elastin to protect it from being 
degraded by elastases. More studies are needed to look at the mechanisms 
of how PGG aids elastin deposition. It will be very useful to find out if PGG 
is playing a catalyst role by holding tropoelastin molecules close to 
degraded elastic fibers and allowing lysyl oxidase to crosslink them and if 
PGG is actually consumed in this process. This analysis can be extended to 
other properties i.e., MMP inhibition and anti-oxidation.  
VII. Finally, the targeting technique used in this research is a result of many years 
of successful testing in various animal models. To utilize this technique of 
targeting elastin damage in other lung disorders like fibrosis and cancer 
could be a way to deliver toxic drugs at significantly lower concentrations 
with a controlled release option. Additionally, nanoparticle surfaces could 
be modified to target known markers to specific cancers [312, 313]. 
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